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Before pharmaceuticals are released onto the marked they have to go through substantial 
testing to ensure their content and safety. The rules and regulations governing the dietary 
supplements industry on the other hand are far less strict, and as of 2013 there are no quality 
demands regarding dietary supplements based on marine oils, such as omega-3 and krill oil 
supplements. Because there is no routine testing of dietary supplements it is interesting to 
investigate weather the content of the supplements match the labelled ingredients and the 
focus of this thesis have been evaluation of the contents of marine oils based products. 
The main constituents of marine oil are fatty acids, phospholipids and triglycerides. Krill oil 
mainly contains essential fatty acids bound to phospholipids, where phosphatidylcholine is the 
most dominant phospholipid.  
A novel method was developed for UPLC-MS analysis of phospholipids in complex lipid 
samples. The methods developed allowed for identification and structural elucidation of 
different PL species and by utilizing MSE technology, rapid qualitative analyses of complex 
lipid samples were made possible. 
By using UPLC-MS it was confirmed that a high proportion of the total content of 
commercial marine oils contained the essential fatty acids EPA and DHA. The study also 
showed that the two different brands of krill oil capsules had very similar content. A raw 
extract intended for commercial use, where the goal was to enrich phospholipids with the 
essential fatty acids EPA and DHA, was also analysed. The study revealed that a higher 
proportion of the total content of the raw extract contained essential fatty acids. As the raw 
extract was obtained from other sources than krill oil this showed that, in addition to krill, 
there are also other marine sources that have a high content of the essential fatty acids EPA 
and DHA. 
Few studies have been done on commercial phospholipid samples such as krill oil and raw 
extract intended for commercial use, and the present study is a contribution to the evaluation 
of marine oils used as dietary supplements and weather the content of the supplements match 
the labelled ingredients. 
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Before pharmaceuticals are released onto the market they need to go through substantial 
testing and the pharmaceutical industry is very well regulated when it comes to development 
of drugs and approval processes. The rules and regulations governing the dietary supplements 
industry on the other hand are far less strict. Although they vary from country to country 
much of the responsibility to ensure the products safety falls on the manufacturer, and 
generally there is no approval needed to produce or sell dietary supplements. There are rarely 
animal and human studies conducted to prove the effect of supplements, which leaves the 
consumers to evaluate the health effects for themselves. A survey was conducted among 
Nordic consumers, on the behalf of the Nordic Council and the Norwegian Food Authorities, 
to explore the consumer’s knowledge, attitude and experience of dietary supplements. The 
survey revealed that more than 50 % of the respondents have concerns about the content of 
dietary supplements and more than 75 % feel they have little or no knowledge about dietary 
supplements (1). However studies have shown that dietary supplements have become an 
established part of people’s daily intake (2) and that supplements based on marine oils are one 
of the most popular and commercially important supplements especially in the Nordic 
countries (1-3). Krill is emerging as one of the newcomers on the market with an ability to 
deliver omega-3 fatty acids. The research done on this type of marine oil is not as extensive as 
the work that has been done on fish oil, but preliminary studies show that this can be a new 
and effective delivery system for essential fatty acids (4).  
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2. Dietary supplements and marine oils 
 
Dietary supplements are products intended to add nutritional value to the diet or have a 
physiological effect on normal body functions (5). Dietary supplements are concentrated 
sources of vitamins, minerals or other ingredients, such as supplements based on marine oils 
and plant extracts. They are sold prepacked and come in a variety of dosage forms. Most 
commonly are tablets, but depending on the physical and chemical properties of the substance 
and compliance of the product, supplements are also found as granules, hard or soft gelatine 
capsules, effervescent tablets or as a liquid.  
The laws and regulations governing the dietary supplement industry are different from the 
ones that relate to pharmaceutical drugs. Dietary supplements can contain some of the same 
substances as pharmaceutical drugs, but then usually in a much lower concentration. 
Pharmaceutical drugs are defined in the Norwegian Drug regulation as “any substance, plant 
drug or product that is claimed to prevent, heal or alleviate disease, disease symptoms or pain, 
or affect human or animal physiological functions” (6). This means that a product is 
considered a drug if it falls under the mentioned definition or if it is presented as a product 
that has the mentioned effects. The laws and regulations regarding pharmaceutical drugs leave 
little room for interpretation, and the safety and quality of the products are strictly maintained. 
Dietary supplements on the other hand falls under the Norwegian law “Lov om matproduksjon 
og mattrygghet mv. (matloven)” that governs food safety. There is a regulation under this law 
that deals specifically with dietary supplements where it is given which vitamins and minerals 
the manufacturers are allowed to include in dietary supplements. This is in compliance with 
the European Union legislation regarding dietary supplements that Norway, as a member of 
the EEA, has agreed to. The maximum limits for the ingredients are also given, in addition to 
requirements concerning production, purity, labelling and marketing.  It is however the 
manufacturers own responsibility that they comply with the legislation. The Norwegian Food 
Safety Authority has the overall responsibility, but supplements do not need to be approved 
before they are made available to the consumer (2) and the quality of the products mainly 
depend on the internal procedures and quality systems of the manufacturers.  
As of 2013 there are no quality demands regarding dietary supplements based on marine oils, 
such as omega-3 and krill supplements. They are not included in the legislation for vitamins 
and minerals and therefor the only real demands the manufacturers need to comply with are 
the requirements for hygiene, production, storage and transport (7). Over the years there has 
been a substantial and steady increase in sales of marine oils and omega-3 products. 
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Bransjerådet for naturlegemidler, an independent Norwegian organisation representing the 
dietary supplement industry, reported that in 2010 marine oils and omega-3 products 
accounted for 22 % of the entire dietary supplements market, and from 2010 to 2011 the sales 
of omega-3 products increased by 30% (8). Even though this category of supplements now 
clearly are an important part of people’s everyday diet there were per 2010 no instances that 
supervised the production or control the omega-3 products that are available to consumers.  
As mentioned the manufacturers of omega-3 and marine oils only need to comply with the 
regulations of the law that governs food safety. As a part of this they also have to ensure that 
the labelling and health claims are correct. In 2010 new regulations concerning health and 
nutrition benefits of dietary supplements was implemented (9), and this legislation is 
harmonised throughout the EEA and EU countries as the “EU Register of nutrition and health 
claims made on foods”. The main ingredients of marine oils, that the manufacturers make 
health claims about, are the essential nutrients eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). According to the EU legislation, if a manufacturer is to claim 
health benefits regarding maintenance of blood pressure and triglyceride levels, the products 
needs to provide DHA and EPA of 2-3 grams when consumed on a daily basis. If claims 
concerning maintenance of normal heart and brain function, brain development of the foetus 
and maintenance of normal vision are made the product needs to provide 250 mg DHA and 
EPA on a daily basis. Because there is no routine testing of dietary supplements it is 
interesting to investigate weather the content of the supplements match the labelled 
ingredients. The focus of this thesis have been marine oils, in particular krill oil supplements, 
and evaluation of the contents.  
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3. Lipids  
 
Dietary supplements such as fish oil and krill oil, are lipid-based supplements. Because this 
category of supplements is a growing trend and an increasing part of people’s everyday diet 
this area represents an interesting research field.  
Even though the research done on lipids is substantial there is still no universally accepted 
definition of the term. Lipids are in general described as a very diverse group of compounds 
and one definition proposed by Christie states that lipids are  “naturally occurring compounds, 
which have in common a readily solubility in organic solvents such as chloroform, benzene, 
ethers and alcohols.” (10). This can be somewhat misleading, as some of the compounds that 
are considered lipids are also soluble in water, e.g. short-chain fatty acids and a definition 
based on more than just solubility would be useful. The same author along with others (10, 
11) have later proposed that the very varied class of lipids would be best defined by structure, 
which is also very useful for chromatographic analysis.  
Christie (10) and O’Keefe (11) divided lipids into two and three major classes; derived, 
simple and complex. Derived lipids are the basic building blocks of simple and complex 
lipids and include fatty acids and alcohols. Simple lipids are lipids that “can be hydrolysed to 
two different compounds”. Complex lipids are structures that “yield more than three different 
compounds on hydrolysis” (11). Included here are the glycerolipids, glycerophospholipids 
and sphingolipids.  
In 2005 the International Lipid Classification and Nomenclature Committee (ILCNC) saw the 
need for a common international language and classification to ease the communication and 
create a joint platform for all the research presented on the field of lipids (12). The committee 
developed a new classification scheme based on structure and function and has organized the 
lipids into eight categories (Table 1), which is now being used internationally by lipid 






Figur 1: The 
general fatty acyl 
structure that is a 
building block for 
many complex 
lipids. R = alkyl 
chain. The X 
moiety depends on 
the fatty acyl class 
Table 1: Revised table of lipid categories of the comprehensive classification system developed by the 
ILCNC (13). 
Category Abbreviation 




Sterol Lipids ST 




Lipids from a range of different sources are included in the classification system. In addition 
to mammalian lipids, non-mammalian sources such as plants, bacteria, fungi, algae and 
marine organisms are represented (13). Only three of the lipid classes are relevant for this 
thesis and will be explained in more detail.  
 
 
3.1. Fatty Acyls 
 
The Fatty Acyls are one of the most important lipid categories because the  
fatty acyl structure represents the main building block for more complex  
lipid structures. The general fatty acyl structure is presented in Figur 1,  
where R represents an alkyl chain and the X will vary for each of the 14  
subcategories of the fatty acyls. This is a very broad class of compounds  
that all have in common the basic fatty acyl structure and the main  
synthesis pathway (12). The fatty acids and conjugates, eicosanoids and  
fatty esters are found in this category. Most commonly known and used  




3.1.1. Structure and nomenclature of fatty acids 
 
The fatty acids are the structurally simplest lipids and some of the most important building 
blocks of more complex lipids. They are “aliphatic, usually straight chain, monocarboxylic 
acids.” (14). Generally the fatty acids contain an even number of carbon atoms in a straight 
chain attached to a carboxyl group in one end and a methyl group in the other end. The most 
common chain-length found in animal tissue is between 14 and 22 carbons (10). Fatty acids 
can also have one or more double bonds of either cis or trans configuration. The naturally 
predominant is the cis configuration (10). There are significant differences in chain-length, 
number of double bonds and their position in naturally occurring long chain fatty acids. This 
means that there is a great variety (15) and more than 1000 fatty acids are known that are all 
structurally different (14).  
Fatty acids containing no double bonds are termed saturated fatty acids. They are usually 
straight-chained compounds, and in animal and plant tissue there are usually 14, 16 or 18 
carbon atoms (10). According to the standard nomenclature developed by the International 
Union of Pure and Applied Chemistry (IUPAC) saturated fatty acids are named systematically 
after the number of carbons atoms in the chain. The carboxyl carbon is marked as number 1, 
and the ending is changed from “e” to “oic” (10, 11). Over the years trivial names, also called 
common names, have been introduced and for some fatty acids they are more frequently used. 
The molecular and structural formula of a saturated fatty acid with 16 carbon atoms is shown 







The recommended systematic name is hexadecanoic acid. This fatty acid is the most abundant 
of the saturated fatty acids and is often referred to by its trivial name, palmitic acid. In 
shorthand nomenclature palmitic acid may be termed ‘C16’, or more precisely ‘16:0’, where 
the zero indicated that there are no double bonds present.  
Unsaturated fatty acids contain one or more double bonds. The double bonds can be found in 
different positions and is specified in the nomenclature along with the double bond geometry, 
which is assigned using cis/trans, or E/Z nomenclature. The double bond position is allocated 




Figure 3: Molecular structure of 9-octadecenoic acid, also called 
oleic acid (18:1 9c) 
in a number of ways. According to the recommended IUPAC rules the double bond position 
is indicated with a number before the fatty acid name the numbering beginning from the 
carboxyl end of the chain (14). The notation  is often used in shorthand nomenclature. The 
shorthand abbreviation for unsaturated fatty acids used throughout this thesis is  
“Number of carbon atoms:number of double bonds position(s) of double bond(s)double bond configuration”. 
The molecular and structural formula of an unsaturated fatty acid with 18 carbon atoms is 






The recommended systematic name is 9-octadecenoic acid, the trivial name oleic acid and the 
shorthand nomenclature is 18:1 9c. For simplicity the stereochemistry is not indicated in the 
figures or throughout the thesis. The  -and n-systems are sometimes used in nomenclature 
and this indicates the double bond positions from the methyl side of the carbon chain. It is 
written -x or n-x, where x is the double bond carbon numbered from the methyl side of the 
carbon chain, e.g. ( -9)-18:1 or (n-9)-18:1 for oleic acid (14). A list of relevant fatty acids 
with their trivial names and shorthand nomenclature is given in Table 2.  
The  -and n-systems are sometimes used in nomenclature and this indicates the double bond 
positions from the methyl side of the carbon chain. It is written -x or n-x, where x is the 
double bond carbon numbered from the methyl side of the carbon chain, e.g. ( -9)-18:1 or (n-
9)-18:1 for oleic acid (14).  A list of relevant fatty acids with their trivial names and shorthand 















































































































































Figure 4: The two main categories of essential fatty acids. The body has the 
ability through several metabolic processes to convert the precursor fatty 
acids to longer chained ones. 
3.1.2. Function and use of fatty acids 
 
The body produces most of the fatty acids that are needed for optimal health, but some fatty 
acids need to be supplied through the diet. These fatty acids are called essential fatty acids 
and can broadly be divided into two different categories, omega-3 and omega-6 fatty acids. 












The n-system has been used as nomenclature as this is the most frequently used when talking 
about essential fatty acids. Omega-3 polyunsaturated fatty acids (n-3 PUFAS) such as 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are to a small extent 
converted through a series of metabolic steps from alpha- linolenic acid (ALA) together with 
their eicosanoidic derivates (16). Arachidonic acid (AA) is the precursor fatty acid in the 
Omega-6 family and are metabolically converted to pro-inflammatory eicosanoids, such as 
prostaglandins (17). The metabolic pathways of these two fatty acids families are similar and 
thus they can compete for enzymes and have an inhibitory effect on each other (16). There 
has been suggested that the ratio between these two families of fatty acids might influence the 
pathogenesis of many chronic diseases and a low omega-6/omega-3 ratio is favourable (18).  
EPA and DHA are the most commonly known essential fatty acids, much because they are 
involved in many processes in the body and play a vital role in health (17). Among others 
they are an important part of the phospholipids in the structure of all cell membranes. They 
also affect the cholesterol and the brain- and eye function. These essential fatty acids are 
precursors for different eicosanoids that influence inflammation, blood pressure and platelet 
function in the body (19, 20). EPA has a total of 20 carbon atoms and five double bonds, 
where the first double bond is located at the third carbon from the methyl end and the 
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shorthand name used throughout this thesis is 20:5Δ5,8,11,14,17, illustrated in Figure 5. DHA has 
a total of 22 carbon atoms and 6 double bonds, where the first double bond is also located at 
the third carbon from the methyl end thus making it an omega-3 fatty acid, illustrated in 








In recent years the fatty acids EPA and DHA have had several health benefits attributed to 
them and for the last three decades much research has been done in this area. Randomised 
controlled trials (RCT), observational- and experimental studies along with meta-analysis and 
systematic reviews have been conducted. There has been suggested that EPA and DHA may 
have a positive effect on total mortality, cardiovascular health and cancer (21-23). A meta 
analysis by Bucher et.al concluded that “Intake of n-3 polyunsaturated fatty acids reduces 
overall mortality, mortality due to myocardial infarction, and sudden death in patients with 
coronary heart disease.” Although more recent evaluations (24, 25) of available information 
and a RCT study by Burr et. al (26) have not ruled out important health effects of omega 3 
fats, there is some doubt with regard to the established health benefits. There is a need to 
investigate for example the mechanism behind and dose needed for possible beneficial 
outcomes and bigger and more robust studies are required to draw definite conclusions. There 
seems to be more benefits related to patients with diabetes, hyperlipidaemia or patients having 
had a myocardial infarction (24) compared to generally healthy persons.  
Guidelines regarding public health both in the UK, the Nordic countries and in America 
include recommendations about oily fish and omega-3 fatty acids (27-29). The American 
Heart Association (AHA) has different recommendations for different patient categories as 
shown in Table 3.  
 
Figure 6: Molecular structure of DHA (22:6Δ4,7,10,13,16,19) 
Figure 5: Molecular structure of EPA (20:5Δ5,8,11,14,17) 
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Table 3:  Summary of recommendations for Omega-3 fatty acids from the American Heart Association. 
CHD = Chronic Heart Disease  
Population Recommendation 
Patients without documented CHD 
 
Eat a variety of (preferably oily) fish at least twice a week. 
Include oils and foods rich in α-linolenic acid (flaxseed, 
canola, and soybean oils; flaxseed and walnuts). 
Patients with documented CHD 
 
Consume ≈1 g of EPA+DHA per day, preferably from oily 
fish. EPA+DHA supplements could be considered in 
consultation with the physician. 
Patients needing triglyceride lowering 
 
Two to four grams of EPA+DHA per day provided as 










Glycerolipids are the largest of the eight lipid categories and include 
all glycerol-containing lipids. The basic structure of glycerol is shown 
in Figure 7.  
This category predominately consist of mono-, di-, and tri-substituted 
glycerols. In these compounds the hydroxygroup of the glycerol is 
esterified, typically by fatty acids. The glycerol backbone will then 
have one, two or three fatty acids attached. There is a stereospecific 
numbering system to describe these compounds, which is shown in 
Figure 7 as well. This group of lipids are the ones most commonly 
found in mammalian storage tissue, and the tri-substituted glycerols, also known as 
triglycerides, are also an important ingredient in dietary supplements (12). 
 
3.2.1. Structure and nomenclature of triglycerides 
 
Triglycerides, also known as triacylglycerols or TAG, are one of the simplest lipid classes and 
are the major building blocks of most natural fats and oils. They are esters of glycerol and 
consist of a glycerol moiety and fatty acids. The fatty acids can all be the same, two can be 
the same or they can all be different, as shown in Figure 8 (14). The recommended systematic 
name for the structure in Figure 8, which has palmitic acid (16:0) in sn-1 position, EPA 
(20:5Δ5,8,11,14,17) in sn-2 position and oleic acid (18:0) in the sn-3 position, is 1-octadecanoyl-
2-(5,8,11,14,17-eicosapentaenoyl)-3-hexadecanolyl-sn-glycerol. The –ic ending id replaced 










Figure 7: Basic structure of 
glycerol.  
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3.2.2 Function and use of triglycerides 
 
All that is mentioned about fatty acids in the previous section applies to the fatty acids in 
these compounds, and triglycerides are undoubtedly a great source of essential fatty acids. In 
animals and most plants triglycerides act as storage lipids and are therefore of great 
importance in physiology as well as in the food industry. Triglycerides are important dietary 






Glycerophospholipids, also called phospholipids, have many 
similarities with the previous category, glycerolipids, but have 
been made a separate group “because of their abundance and 
importance as membrane constituents, metabolic fuels, and 
signalling molecules” (12). They have a similar skeleton but 
differ, usually at the sn-3 position, where phospholipids (PLs) 
have what is called a polar head group. The polar head group 
consists of a phosphate group and usually an organic base or 
polyhydroxy compound (11). The basic structure of 
phospholipids is shown in Figure 9. There are several classes 
of phospholipids and they are most commonly divided into 
groups based on the characteristics of the polar head group. 
Attached to the sn-1 and sn-2 positions on the glycerol backbone 
are often two ester-linked fatty acids.  
 
3.3.1. Structure and nomenclature of phospholipids 
 
All phospholipids (PLs) contain a glycerol backbone, a phosphate group and a polar head 
group that is attached to the phosphate group. This makes them di-glycerides and in most 
phospholipids the phosphate group is linked to the sn-3 position (11). The glycerol backbone 
becomes chiral when the two substituents at sn-1 and sn-3 position are different, but again for 
Figure 9: The general structure of a 
phospholipid where X denotes the 
part of the polar head groups that 
differs between the individual PL 
species.  
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simplicity this is not indicated throughout the thesis. PLs can have fatty acids attached in both 
sn-1 and sn-2 position or only in one position. When there is only one fatty acid present, 
usually in sn-1 position, they are termed lysophospholipids (lysoPLs) (10). PLs are termed 
complex lipids and have an amphipathic nature having both hydrophobic and hydrophilic 
groups. The relevant and most common phospholipids for this thesis are shown in Table 4.  
 
Table 4: Structures of phospholipids relevant for the present thesis.  
Class Phosphatidylcholine Phosphateidylethanolamine 




Abbreviation PC PE 
 
Phospholipids are systematically named and often the abbreviations for the head group classes 
are used (PC = phosphatidylcholine etc.). Figure 10 shows a phospholipid with PC as a polar 
head group and the fatty acid 16:0 (palmitic acid) in sn-1 position and 22:6Δ4,7,10,13,16,19  








Figure 10: 1-hexadecanoyl-2-(4,7,10,13,16,19)-docosahexaenoyl-sn-glycero-3-phosphatidylcholine 
 
The fully systematic name is 1-hexadecanoyl-2-(4,7,10,13,16,19)-docosahexaenoyl-sn-
glycero-3-phosphatidylcholine. The more convenient abbreviation 16:0-22:6Δ4,7,10,13,16,19 PC 





3.3.2. Function and use of phospholipids 
 
Phospholipids are amphipathic in nature and are a 
significant part of animal cell membranes where 
they form what is called the lipid bilayer. This lipid 
bilayer is the structural basis for all animal cells and 
is illustrated in Figure 11. The polar moiety of the 
lipid will be facing out and the neutral fatty acid 
“tails” will be facing inwards. PC is in abundance in 
the cell membranes with PE as the second most 
frequent phospholipid class in animal tissue (10). 
PEs are also important messengers in the endocannabinoid signalling system (14).  
The main digestion of phospholipids occurs in the small intestine, and dietary 
phosphatidylcholine is rapidly and almost completely absorbed (30). Phospholipases, mainly 
Phospholipase A2, hydrolyses the PLs in stereospecific positions. Phospholipase A2 interacts 
with PLs at the sn-2 position to yield free fatty acid and lysoPC.  
These are both absorbed into the mucosal cells and incorporated into the chylomicron surface 
layer. In the bloodstream the PLs and free fatty acids are released from the chylomicrons and 
can be taken up by various tissue. There has been suggested that the chemical form of the 
phospholipid can influence the distribution of FAs to different tissues (31). PLs do not need 
bile salts to solubilize and form micelles, which aids the absorption and bioavailability (32). 
Because they are building blocks of all cell membranes they are also easily incorporated into 
different tissues.  
PLs are used in a variety of areas and are often referred to as lechitins in the industrial field. 
They are commercially available for use in food industry, cosmetic and pharmaceutical fields 
(4). In the pharmaceutical industry it is utilized in drug delivery systems as nanocarriers and 
in cosmetics the conditioning and softening characteristics are exploited. Being surface-active 
compounds they are often used in nutritional fields as emulsifiers, lubricants and also for 
wetting and dispersion purposes (4).  Phospholipids are naturally occurring in a range of 
foods but are also used as a food additive, for example in infant formulas. As a dietary 
supplement PLs are used to deliver essential fatty acids and one of the most frequently used 
phospholipids is phosphatidylcholine. It has been suggested that a high content of essential 
fatty acids such as EPA and especially DHA in the sn-2 position of dietary phospholipids is 
beneficial (33). Choline (Figure 12), which is the polar head group of phosphatidylcholine 
Figure 11: Phospholipids in the lipid bilayer 
of celle membranes 
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and phosphatidylcholine itself, are also essential 
nutrients and has a variety of functions in the human 
body. Choline affects cell structure, neurotransmitter 
synthesis, inflammation and cognitive function (34). It 
is also thought to influence diseases such as liver and 
heart disease (34). 
 
 
3.4. Lipids from krill oil 
 
Krill oil represents a new branch of marine oils that for the last few years have generated a lot 
of interest because of the unique form of lipids in these omega-3 products. The term krill is 
used to describe more than eighty species of crustaceans, which have a shrimp-like 
appearance. The commonly known “Arctic krill” or Euphausia Superba is the species of krill 
that is mostly harvested for human consumption (35) and one of the most commercially 
interesting species because of its abundance. Even with their small size they form huge 
surface swarms, and the density of krill can be as high as 1 million animals per cubic metre of 
water and stretch for several kilometres (35).  They feed on marine algae (phytoplankton) that 
synthesize omega-3 fatty acids, DHA and EPA among others, and accumulate these in their 
eggs and body (35, 36). Antarctic krill is an important part of the Southern Ocean eco system 
and is a valuable food source for whales, seals, fish, squid and birds (35, 37).  
The nutrition composition of krill has been investigated and it has been found that this is a 
great source of lipids and essential fatty acids. Almost all studies of krill found that the main 
lipid classes were phospholipids, triglycerides and free fatty acids (38). Euphausia Superba 
contains more than 40% phospholipids were phosphatidylcholine is most abundant. The 
dominating fatty acids have been reported to be 16:0 among saturated fatty acids and 18:1, 
20:5 and 22:6 among the unsaturated. The positional analysis of fatty acids in PC and PE 
showed that the saturated fatty acids are mainly attached in sn-1 position while the 
unsaturated fatty acids are commonly linked to the sn-2 position (38).  
  
Figure 12: General structure of choline 
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3.5. Phospholipids vs. triglycerides used as dietary supplements  
 
Krill oil represents a valuable source of omega-3 fatty acids and studies have shown that  
30 - 65 % of the fatty acids in krill are attached to a phospholipid moiety while in commercial 
fish oil most of the fatty acids are bound as triglycerides (35). More and more studies are 
emerging where the bioavailability of different omega-3 formulations are compared. Studies 
have suggested that the chemical form of the lipid influences absorption and bioavailability. 
Fatty acids may be better absorbed from dietary PL than from TG as indicated in studies done 
on new-born infants (39), and also when infants receive formula where essential fatty acids 
were bound to PL this has shown a higher absorption. (40). Three clinical trials have included 
krill in bioavailability studies. A relatively small study by Schuchardt et al. indicated that 
DHA and EPA were better absorbed from krill than re-esterified triglycerides (41). Maki et al. 
found that DHA and EPA from krill oil was absorbed at least as well as essential fatty acids 
from menhaden oil (TG) and showed a trend towards greater increase in plasma DHA and 
EPA with krill oil (42).  A third study done by Ulven et al. found no statistically significant 
evidence that essential fatty acids from PLs are absorbed or have a better health effect than 
essential fatty acids in TG form (39). All though the research done on humans is limited, there 
is more evidence from animal data to support that the bioavailability of krill oil is superior 
(43, 44) and because PLs don’t require digestive enzymes to be absorbed this would be 
expected to increase the bioavailability.  
The emerging studies indicate that the bioavailability of essential fatty acids in PL form and 
from krill oil are comparable to TG and are a promising way of delivering fatty acids. In 
addition phosphatidylcholine is an essential nutrient in itself. More randomised studies should 
be executed on a study population with for example elevated blood TG levels and lowered 
HDL-cholesterol and in addition other biomarkers such as inflammation, oxidative stress and 





4. Analysis of lipids 
 
Mass spectrometry (MS) has proven to be an effective tool for analysis of both simple lipids 
and more complex lipid structures. Coupled with the power of ultra performance liquid 
chromatography (UPLC) it is possible to gain information on the polar head group and the 
fatty acid substituents on the glycerol backbone. The identification of the phospholipid 
profiles is important to be able to evaluate the nutritional properties of food ingredients and 
products including dietary supplements (45). Dietary supplements, recommended as part of a 
healthy diet, often consist of very complex mixtures of different lipid structures.  Krill 
supplements delivers essential fatty acids bound to phospholipids and often these components 
represent close to half of the declared content.  
 
 
4.1. Ultra performance liquid chromatography 
 
UPLC is a further development of high performance liquid chromatography (HPLC). HPLC 
is a separation technique where analytes are separated based on partition between a liquid 
mobile phase and a solid stationary phase. The distribution between the stationary phase and 
mobile phase depends on the nature of the analyte, the composition of the mobile phase and 
the properties of the stationary phase. The stronger the affinity for the stationary phase the 
longer the retention time will be (46). If a sample contains more than one analyte the 
difference in their chemical properties and affinity for the stationary phase are exploited to 
separate them. A liquid sample is driven through a column packed with a stationary phase by 
liquid flow at high pressure provided by mechanical pumps. The advancement of UPLC, 
using columns with smaller particle sizes and instrumentation that can withstand higher 
backpressures, increases the resolution, speed and sensitivity of liquid chromatography (47).  
UPLC is a useful tool for analysing lipids. Compared to older methods of separation, UPLC 
minimises oxidation of phospholipids and also reduces contamination (48). Both normal-
phase UPLC (NP-UPLC) and reversed-phase UPLC (RP-UPLC) can be used when analysing 
lipids. NP-UPLC separates lipid classes based on polarity. The lipids elute in order of 
increasing polarity according to their respective classes. For the present thesis the relevant 
lipid classes would elute in the following order TG<PL<FA. The phospholipids also elute 
according to their individual classes, resulting in PEs eluting first and PCs eluting last (45). 
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RP-UPLC separates the lipids based on lipophilicity. The more lipophilic a compound is the 
more it is retained on the column. Thus in addition to polar functional groups, the fatty acids 
chain length and number of double bonds determines the elution sequence (48). The elution 
order for the relevant lipid classes is FA<PL<TG, however there is potential for overlapping 
of the different lipid classes. Lysophospholipids, containing only one fatty acid, also elute 
early in the chromatogram before the PLs containing two fatty acids. Depending on the fatty 
acyl groups attached overlapping of different PL groups is possible. As opposed to NP-UPLC, 
RP-UPLC allows for separation of each lipid class into individual species and is a suitable 
system for complex mixtures of lipids and has been the technique of choice for industrial and 
bio analytical analysis (49).  
 
 
4.2. Mass spectrometry 
 
The technique of mass spectrometry is based on separation of ions in gas phase according to 
their mass-to-charge ratio, m/z. The basic principle of MS is to generate charged ions and 
separate them by exposing them to dynamic or static electric fields (50). A mass spectrometer 
consists of an ion source, a mass analyser and a detector.  
All analyses performed in the present thesis have been performed using electrospray 
ionisation (ESI). ESI takes place under atmospheric pressure outside the mass spectrometer. 
The analytes are usually in a solution that is transferred through a stainless steel capillary with 
high voltage applied so that an aerosol is formed. This aerosol formation is often improved by 
using a nebulising gas, usually nitrogen. The aerosol consists of a large number of small 
charged droplets. Between the capillary tip and mass analyser there is a cylindrical electrode 
with a counter electrode that draws the droplets towards the sampling cone. As the droplets 
cross the space between the needle tip and the cone the mobile phase solvent evaporates. This 
leads to the shrinking of the droplets and with the aid of a heated drying gas the charge 
density of the droplets reach a critical point and a so called columbic explosion occurs. This 
happens repeatedly until only the molecular species are left. Negatively charged species are 
formed if the potential applied to the steel capillary is negative. Usually the loss of a proton 
leads to the formation of [M-H]-. Likewise when applying positive charge commonly a 
protonated molecular specie, [M+H]+ is formed.  
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In the mass analyser the charged species are separated because of the different deflection in 
the magnetic or electric field. A time-of-flight (QTOF) mass analyser was used in the analysis 
of lipids in the present thesis. In the QTOF a linear quadropol was placed in front of a 
reflectron time-of-flight (TOF). A collision cell was located between the quadropole and the 
TOF analyser to induce fragmentation in MS/MS experiments. In a linear quadropole a 
continuous ion beam is sent though four parallel metallic rods where the opposing pair are 
connected electrically (50). The two pairs are each held at the same constant voltage and a 
fluctuating radio frequency (RF) voltage (46). This leads to periodic attraction and repulsion, 
and the ions are deflected in complex trajectories allowing only ions with particular m/z ratio 
to pass through at specific values of the applied voltages. 
In a TOF an ions m/z ratio is determined via time measurement. Ions of different m/z are 
accelerated in pulses by an electric field and dispersed in time during their flight along a path 
of known length. Ions with the same charge are accelerated to the same kinetic energy, and 
assuming that all ions start their flight within a sufficiently short time interval the ions that 
have a low m/z value arrive earlier at the detector than the ions with a high m/z (50). In an 




4.3. ESI-MS of lipids 
 
With the introduction of electrospray ionization mass spectrometry (ESI-MS) the earlier more 
time-demanding and nonspecific technics are outdone and makes it easier to analyse intact 
phospholipids (48). Being a soft ionisation technique ESI can ionise lipids with little to no 
fragmentation, which generates molecular ions of high intensity and makes structure 
determination easier because most likely the ions observed are molecular ion species (51). 
Although not strictly molecular ions, because neither has the correct molecular mass of the 
lipid, they are still referred to as molecular ions because most often they have the correct 
molecular mass, plus or minus a proton. PC is the exception and will be explained in more 
detail later. In positive ESI mode mainly information about the phospholipid head group is 
obtained. In negative mode more information on structure and the position of the fatty acids 
on the glycerol backbone can be determined when utilizing MS/MS. Class specific fragments 
are also more easily obtained in negative mode (52).  
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Mass spectrometry is frequently used because of it’s high sensitivity and specificity (45). To 
gain more structural information, collision-induced dissociation (CID) is often used as a 
fragmentation technique and provides information on the polar head group and the fatty acid 
substituents on the glycerol backbone.  
Many class specific fragments can be identified and can be used in the characterisation 
process (52). The literature on negative ionization of PLs is more extensive than for positive 
ionisation. For all PL classes there will be produced a high amount of deprotonated molecules 
[M-H]-, except for PC, which has a permanent positively charged nitrogen. The formation of 
negative ions requires either removal of the quaternary nitrogen or the addition of another 
anionic site in the PC structure. In negative mode PC have been known to yield [M-CH3]- ions 
as a result of the demethylation of choline, but [M-H]- have also been detected. Addition of 
another anionic site can be achieved by the formation of adducts with other anions and both 
[M+Cl]- and  [M+acetate]-  have been detected depending on the buffer agent used in the 
mobile phases (48, 53, 54). When an adduct formation is observed, [M-CH3]- is also often 
observed. This is likely to be because of collisional decomposition of the anionic acetate, 
where the anion abstracts the methyl group from the quaternary nitrogen. This can be used as 
a diagnostic for the presence of the choline moiety in PC (54). A summary of the most 
important class specific product ions predicative of the polar head groups formed upon CID is 
presented in Table 5.  
 
Table 5: Characteristic product ions obtained from negative  
ESI-MS/MS and ESI-MS/QTOF of PLs. (55) 
PL class PC PE 
Molecular ion [M-H]- 
[M-CH3]- 
[M+Cl]- 
[M+OAc]-   
[M-H]- 








Other common negative ion decomposition ions from PLs include the loss of the fatty acids in 
sn-1 and sn-2 positions (Reactions 1a and 1b).  
 
[M-H]- ! R1COO-           (1a) 
[M-H]- ! R2COO-           (1b) 
 
Either one of the fatty acids might also leave the negative charge on the PC backbone to yield 
a lysophospholipid (Reactions 2a and 2b). 
 
[M-H]- ! [M – H – R1COOH]-        (2a) 
[M-H]- ! [M – H – R2COOH]-            (2b) 
 
Either of the acyl chains may also be lost as a ketene, which leaves a –OH group on the 
charged lysophospholipid that is left (Reactions 3a and 3B).   
 
[M-H]- ! [M – H – Rʹ′1C=C=O]-        (3a) 
[M-H]- ! [M – H – Rʹ′2C=C=O]-        (3b) 
 
All the fragmentation mechanisms mentioned are valid for [M-CH3]- as a precursor ion and 
also for fragmentation after adduct formation, for example with acetate anions.  
The relative yield of the difference species have by some investigators been used to assign the 
fatty acids to either the sn-1 or sn-2 position. Previous studies have revealed a potential for 
structural characterisation based on the ratio of the carboxylate anions, where the loss f the 
fatty acid in sn-2 position would be more likely to occur and thus yield a higher signal (48).  
However it has been debated weather this can be used without caution as other studies have 
seen that the relative ratios of the carboxylate anions are dependent on the degree of 
saturation, the total chain length and also the collision energy applied to the experiment (48, 
56). The results indicating that the collision energy may influence the fragmentation pattern, 
where at low collision energies there is a preferential loss of the sn-2 carboxylate anions and 
at higher CEs there is a preferential loss of the sn-1 anion. This difference observed however 
may also be explained by further decomposition of the sn-2 carboxylate anion (48, 56). 
Because different R2COO-/ R1COO- ratios also have shown to vary between the different PL 
classes this might suggest that there are interactions between the acyl chains and the polar 
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head groups as well.  Because of many observations of the preferred loss of the fatty acid in 
sn-2 position (reaction 1b) and also the dominant lysoPL after loss of a neutral fatty acid in 
sn-2 position (Reaction 3b) this indicates a trend. It is worth noticing that many of these 
studies have analysed PLs that contain mono- and di-unsaturated fatty acids. Analysis of PLs 
with polyunsaturated fatty acids could result in a much more difficult and complex 
interpretation of spectra upon CID (57). Thus care must be taken when interpreting the 
R2COO-/ R1COO- ratio. As the ratio seems to be dependant on both the characteristics of the 
PL itself and the experimental conditions it is difficult to make general conclusions for PLs as 
a whole and for the individual PLs of the different PL classes.  
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5. Aim of thesis  
 
The general aim of the thesis was to develop UPLC and MS methods that enabled structure 
characterisation of phospholipids in complex lipid samples. Dietary supplements that had a 
high concentration of phospholipids were selected for the study. 
 
Specific sub-goals: 
" Develop a chromatographic method that can separate lipids in complex krill oil 
samples  





6. Materials and methods 
 
Molecular structures are derived from http://www.chemspider.com/ (14.05.2014), provided 
by the Royal Society of Chemistry or drawn with molecular editing software ChemDraw 
version 2.0.1. developed by PerkinElmer. The molecular structures for the standards from 
Avanti Polar Lipids are taken from the product information sheets for the specific compounds, 
found at 
http://avantilipids.com/index.php?option=com_content&view=article&id=100&Itemid=108 
(12.04.2014). Molecular and monoisotopic masses were calculated using a free online 
molecular mass calculator, http://www.lfd.uci.edu/~gohlke/molmass/?q=C29H58NO8P 
(12.05.2014), developed by Christoph Gohlke at The Laboratory for Fluorescence Dynamics, 





The phospholipid standards 18:0-22:6Δ4,7,10,13,16,19 PC (1-stearoyl-2-docosahexaenoyl-sn-
glycero-3-phosphocholin), 16:0-18:1Δ9 PC (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine), 18:1Δ9-0:0 PC (1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine), 16:0-
18:1Δ9 PE (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine) all dissolved in 
chloroform and 16:0-0:0 PE (1-palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine) 
dissolved in chloroform, methanol and water were all purchased from Avanti Polar Lipids 
(Alabaster, Alabama, USA). Lipoid E80 standard (Mixture of lipids extracted from egg with 
approximately 80 per cent phosphatidylcholine. (See Appendix 1 for details) were purchased 
from Lipoid GmbH (Ludwigshafen, Germany). Structures, molecular formula, exact masses 
and CAS registry numbers for the most relevant compounds are shown in Table 6.  
Solvents for UPLC were Methanol hypergrade for LC-MS, Triethylamine for synthesis, 
Ammonia solution 28-30% for analysis, 2-propanole LiChrosolv gradient grade for liquid 
chromatography and Ammonium Acetate for analysis all purchased from Merck (Darmstadt, 
Germany). Acetonitrile HiPerSolv Chromanorm for HPLC was purchased from VWR BDH 
Prolabo (Leuven, Belgium). Water was obtained from a MilliQ purification unit from EMD 
Millipore Corporation (Billerica, MA, USA). Nitrogen was obtained from a Nitrogen 
Generator NM 32 LA (Peak Scientific) and Argon gas (99.99%) from AGA (Oslo, Norway). 
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Table 6: Molecular structure, formula, mass and CAS registry number of the chemical standards.  












C48H84NO8P 833,5935 59403-52-0 
 






































Krill oil capsules were purchased from different health food shops. The product content 
declared on the packages is shown in Table 7.  
 
Table 7: Content of krill oil capsules declared on the packages 
Product name Rimfrost Krill Oil 
(Euphausia Superba) 
1 capsule 
Life Krill Oil 
(Euphausia Superba) 
1 capsule 
Marine phospholipids (mg)  210 200 
Omega-3 fatty acids (mg) 120 110 
EPA (mg) 60 60 




Raw extract material was donated by a Norwegian based company, who’s name remains 
confidential and throughout the thesis will be known as AN. The raw extracts donated were 
given the anonymous names AN1 and AN2. The manufacturers goal was to develop a high 
quality marine oil product, and differences between the raw extract materials and the 
information about extraction methods were confidential and not provided. The aim of the 






Ultra performance liquid chromatography was performed using a Waters Acquity Ultra 
Performance LC I-Class instrument. Five different columns, all purchased from Waters corp. 
(Milford, MA, USA) were used to find optimal separation for different phospholipids.  
 
Table 8: Properties of columns used in method development 
UPLC-column   Properties 
Acquity UPLC® BEH C18 column  Dimensions:  2,1 x 100 mm 
 Particle size:  1,7 µm 
Acquity UPLC® BEH Amide column  Dimensions:  2,1 x 100 mm 
 Particle size:  1,7 µm 
Acquity UPLC® BEH C18 VanGuard  
Pre-column 
 Dimensions:  2,1 x 5mm 
 Particle size:  1,7 µm 
Acquity UPLC® BEH C18 column  Dimensions:  2,1 x 50 mm 
 Particle size:  1,7 µm 
Acquity UPLC® BEH C18 column  Dimensions:  1 x 150 mm 
 Particle size:  1,7 µm 
 
Mass spectrometric detection was conducted on a Waters Xevo G2 Q-TOF with an 
electrospray ionization source. The software used for analysis was MassLynx version 4.1.  
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7. Method development 
 
The phospholipid standards were used to find the optimal conditions for separation and mass 
spectrometric analysis of phospholipids. These methods were then applied to unknown krill 
oil samples and raw extracts to identify the different phospholipid classes and try to determine 
their structures based on literature and information from chromatograms and mass spectra.  
 
 
7.1. Phospholipid standards analysed with UPLC-MS  
 
All standards were stored under nitrogen at -18°C in the dark to keep oxidation to a minimum. 
The phospholipid standards were made fresh approximately every third day.  
Operating conditions for all full scan TOF-MS analysis are shown in Table 9.  
 
Table 9: Parameters for full scan TOF-MS mode 
Conditions Parameters 
Capillary (kV) 0.6 
Sampling cone (V) 55 
Extraction cone 4 
Source temperature (C) 130 
Desolvation temperature (C) 350 
Cone gas (Lh-1) 20 
Desolvation gas (Lh-1) 800 
Low Mass (m/z) 100 
High mass (m/z) 1200 
Scan time (Sec.) 0.25 
Data Format Centroid 
 
Nitrogen was used as the desolvation and cone gas. Direct infusion of available phospholipid 
standards was used to find the optimal cone voltage. The ESI was operated in negative mode 
for all samples. During MS/MS experiments Argon was used as collision gas, and the 
collision energy was varied for the different standards and analytes.  Leucine enkephaline 
(m/z 554.2651 in negative ionization) was used as lock spray. Full scan MS, MS/MS and MSE 
Continuum was utilized. MSE is a technique were both precursor and fragment mass spectra 
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are simultaneously acquired by alternating between high and low collision energy during a 
single chromatographic run. When using MSE mode it was not necessary to pre-select 
precursor ions. The parameters for MSE mode were the same as for MS and MS/MS apart 
from the data format, which was set to continuum. The low collision energy was off and the 
high collision energy set to 28 (V).  
 
7.1.1. Preliminary experiments 
 
During the initial experiments the standard E80 from lipoid was analysed. This standard was 
tested with different mobile phase compositions and used to develop gradient profiles for 
further lipid analysis. The lipid standards were dissolved in methanol or ethanol and as much 
0.1% ammonia solution as needed for complete dissolution. 
E80 was first analysed with the Acquity UPLC BEH C18 100 mm column using two 
different mobile phase compositions. Mobile phase composition 1 consisted of water and 
methanol with 0.1% ammonia and is displayed in Table 10. 
 
Table 10: Mobile phase composition 1 
Mobile phase A Water with 0.1 % ammonia 
Mobile phase B Methanol with 0.1 % ammonia 
Column temperature 50°C. 
 
Different gradient profiles were tested where the initial conditions were varied. These are 













Table 11: Gradient profiles used for analysis of E80 (10 µg/ml) on Acquity UPLC BEH C18  





Mobile phase A 
Water with 0.1% ammonia 
Mobile phase B 














Mobile phase A 
Water with 0.1% ammonia 
Mobile phase B 














Mobile phase A 
Water with 0.1% ammonia 
Mobile phase B 














Mobile phase A 
Water with 0.1% ammonia 
Mobile phase B 











Neither of these gradients produced chromatograms that were possible to analyse or gain 
relevant information from. There was little separation of different lipid compounds and few, 
not distinct peaks of low intensity. The few peaks detected were broad with long tails, 
showing poor selectivity. This is displayed in Appendix 2.  
In mobile phase composition 2 the buffer component was changed to Triethylamine (TEA) 
and tested on the same Acquity UPLC BEH C18 100 mm column. 
 
Table 12: Mobile phase composition 2 
Mobile phase A Water with 2% TEA 
Mobile phase B Methanol with 2% TEA 






The E80 standard was tested using gradient displayed below in Table 13.  
 





Mobile phase A 
Water with TEA 
Mobile phase B 










However none of the experiments gave results that could be used for further analysis and as a 
result of this a shorter column was tested. The Acquity UPLC®  BEH C18 VanGuard Pre-
column was employed as it was suspected that the lipid standards did not elute from the 
longer 100mm column. Because TEA gives a lasting signal in the LC-MS instrument when 
run in positive mode, it was attempted to keep the concentration of TEA as low as possible to 
avoid contamination in other analyses. Six different concentrations of TEA were tested, 0.02 
%, 0.05%, 0.10%, 0.50%, 1% and 2%, where 2% proved the best. Two different gradient 
profiles, shown in Table 14, were developed where the latter proved the best. 
 
Table 14: Gradient profiles for E80 (100 µg/ml) tested on Acquity UPLC BEH C18  





Mobile phase A 
Water with 2% TEA 
Mobile phase B 














Mobile phase A 
Water with 2% TEA 
Mobile phase B 










The first sign of separation of lipids was achieved using this method and the chromatogram is 
shown in Appendix 3. The efficiency of this column for analysing lipids was not optimal as 
there were overlapping peaks that clearly contained more than one compound.  
On the basis of this a longer column was tested to gain better separation of the compounds in 
the lipid mixture. The Acquity UPLC BEH C18 50 mm column was tried using mobile 
phase composition 2 with 2% TEA. The gradient profiles were varied and the optimal 
gradient is displayed below in Table 15. 
 32 
 
Table 15: The gradient profile that provided the best separation of lipid compounds in the E80 standard 





Mobile phase A 
Water with 2% TEA 
Mobile phase B 










The chromatogram is shown in Appendix 4. Even though the peaks shapes are far from 
optimal and visibly contain several compounds it was possible to locate different lipid 
compounds. This proved that a longer column was more efficient for analysing a sample with 
different lipid components. Other gradient profiles that were tested but did not provide 
sufficient separation are also displayed in Appendix 4.  
 
7.1.2. Analysis of phosphatidylcholine standards 
 
The three phosphatidylcholine standards 18:0-22:6Δ4,7,10,13,16,19 PC, 16:0-18:1Δ9 PC and 
18:1Δ9-0:0 PC from Avanti was used as a basis for development of optimal chromatography 
and MS methods for more complex phospholipid samples. To be able to identify the 
structures in complex lipid samples good chromatography is necessary, and a method was 
developed using two different mobile phase compositions and three different columns. All PC 
standards were dissolved in ethanol and 0.1% ammonia solution (50:50).  
 
Development of UPLC method for analysing phosphatidylcholine standards 
Mobile phase composition 2 
The short Acquity UPLC®  BEH C18 VanGuard Pre-column was tried first and the 
gradient profile that provided the best chromatography for the E80 standards (Table 15) was 
optimized further. It was shortened and a wash out period of 7 minutes with 100% methanol 






Table 16: Optimal gradient for analysing PC standards on Acquity UPLC  





Mobile phase A 
Water with 2% TEA 
Mobile phase B 








 100 % 
15 0.6 0 % 100% 
 
This gradient was used in all further analysis of PC standards. All PC standards provided 
chromatograms with one distinct peak with little to no tailing. Even though the intensity of the 
peak was high there was still a lot of background noise recorded. The chromatograms are 
displayed in Appendix 5.  
When the longer Acquity UPLC BEH C18 50 mm column was employed this resulted in 
longer retention times, from approximately 4 minutes to 7.08 minutes for 18:0-
22:6Δ4,7,10,13,16,19 PC, from approximately 3.6 to 7.02 minutes for 16:0-18:1Δ9 PC and from 
approximately 0.29 to 2.38 minutes for 18:1Δ9-0:0 PC. The retention times are only 
approximate because with this method the peaks were broad. There was also less background 
noise recorded. The chromatogram for 18:0-22:6Δ4,7,10,13,16,19 PC is illustrated in Appendix 6. 
When all three standards where mixed and analysed in one sample, it was difficult to tell 
18:0-22:6Δ4,7,10,13,16,19 PC and 16:0-18:1Δ9 PC apart just by looking at the chromatogram as 
they elute almost at the same time. This is also displayed in Appendix 6. 
 
Mobile phase composition 3 
A third mobile phase composition was tested with the PC standards. This contained water, 
acetonitrile, isopropanol and ammonium acetate as a buffer and is displayed in Table 17. The 
flow was set to 0.5 ml/min because this mobile phase composition generated more 
backpressure.   
 
Table 17: Mobile phase composition 3 
Mobile phase A Acetonitrile/Water (40/60, v/v) with 10 mM Ammonium Acetate 
Mobile phase B Acetonitrile/Isopropanol (10:90, v/v) with 10 mM Ammonium Acetate 
Column temperature 50°C.   
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This mobile phase composition was tried because, as seen with the E80 standards, the lipids 
were difficult to separate and elute from the columns. Isopropanol is a stronger eluent than 
methanol when using C18 columns. Two different gradient profiles, illustrated in Table 18 
and Table 19 were tested, also using the Acquity UPLC BEH C18 50 mm column. 
 





Mobile phase A 
Acetonitrile/Water (40/60, v/v) 
with 10 mM Ammonium Acetate 
Mobile phase B 
Acetonitrile/Water (40/60, v/v) 










The 10-minute gradient was tested with all three PC standards (10 µg/ml), resulting in 
improved chromatography. The retention time for all standards changed and the peaks had 
higher intensity. For 18:0-22:6Δ4,7,10,13,16,19 PC and 16:0-18:1Δ9 PC there were some 
background noise but the peak from the precursor ion was easy to locate. The chromatograms 
are displayed Appendix 7. All three standards were mixed together and analysed with a longer 
30-minute gradient, which is displayed in Table 19. 
 





Mobile phase A 
Acetonitrile/Water (40/60, v/v) 
with 10 mM Ammonium Acetate 
Mobile phase B 
Acetonitrile/Water (40/60, v/v) 










Also with this mobile phase composition the 18:0-22:6Δ4,7,10,13,16,19 PC and 16:0-18:1Δ9 PC  
standards co-eluted. As seen from the individual spectra in Appendix 7 the retention times are 
quite similar, 5.19 and 5.26 minutes respectively, and in a mixture they yielded one 
unsymmetrical peak. Compared to mobile phase composition 2 the chromatographic 
separation was better as it was more apparent that the peak contained two compounds. The 
intensity of the signal was higher as well. This is displayed in Appendix 8.  
To be able to differentiate between various PC compounds in a mixture of phospholipids with 
fatty acids in both sn-1 and sn-2 position better chromatographic separation was desirable. 
The Acquity UPLC®  BEH C18 150 mm column in addition to being longer had a smaller 
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inner diameter. To cope with the smaller inner diameter the column temperature was changed 
to 60°C. The gradient profile used was an optimised version of the 30-minute gradient used 
with the previous column.  
 
Table 20: Gradient used for Acquity UPLC®  BEH C18 150 mm column with  





Mobile phase A 
Acetonitrile/Water (40/60, v/v) 
with 10 mM Ammonium Acetate 
Mobile phase B 
Acetonitrile/Isopropanol (10:90, v/v) 














The chromatography was far better using this longer column and the chromatogram for 18:0-
22:6Δ4,7,10,13,16,19 PC, displayed in Appendix 9, showed a more symmetrical peak for the 
phospholipid standard. The peak was narrower proving this column was more efficient for 
analysing PC standards. The optimal UPLC conditions for analysing PC standards are 
summarised below. 
 
Table 21: Column and mobile phase composition for optimal analysis of PC standards 
Column 
Column temperature 
Acquity UPLC BEH C18 150 mm column 
60 °C 
 





Mobile phase A 
Acetonitrile/Water (40/60, v/v) 
with 10 mM Ammonium Acetate 
Mobile phase B 
Acetonitrile/Isopropanol (10:90, v/v) 
















MS method development for phosphatidylcholine standards 
 
To develop MS methods for identifying different structures in phospholipid samples both MS 
and MS/MS experiments were set up. Full scan MS was used to find the precursor ions and 
MS/MS was used to gain information on the fatty acid components and if possible their 
position on the glycerol backbone. Whenever MSE was utilized this information was gained 
during a single chromatographic run.  
 
Precursor ion detection 
The conditions for all full scan TOF-MS data were the same as in the preliminary experiments 
and shown in Table 9. The initial experiments were performed using mobile phase 
composition 2 (Table 12) and from the full scan MS spectra the precursor ions for the three 
different PC standards were detected. These are summarised in Table 23. For all full scan MS 
experiments both [M-H]- and [M-CH3]- were visible. When MSE mode was used for analysis 
of PC standards both [M-H]- and [M-CH3]- were visible, but the dominant precursor ion was 
[M-H]- (Appendix 10).  
 
Table 23: Precursor ions detected for PC standards (10 µg/ml) using mobile phase composition 2.  
PC standards [M-H] - [M-CH3] - 
18:0-22:6Δ4,7,10,13,16,19 PC 832 818 
16:0-18:1Δ9 PC 758 744 
18:1Δ9-0:0 PC 520 506 
 
Changing to mobile phase composition 3 altered the detected precursor ion for all PC 
standards. When using ammonia acetate as a buffer, the acetate anion (OAc) formed an 
adduct with phosphatidylcholine because of it’s permanently charged nitrogen (Figure 13). In 
full scan MS mode there were two precursor ions observed for all three PC standards, 
[M+OAc]- and [M-CH3]-. A summary of the precursor ions observed using this mobile phase 
composition is shown below in Table 24 and spectra are displayed in Appendix 11. These 
precursor ions had a higher intensity than the ones observed when using mobile phase 
composition 2. 
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Figure 15: Expected fragmentation 16:0-18:1Δ9 PC upon CID 
 
Table 24: Precursor ions detected for PC standards (10 µg/ml) using mobile phase composition 3.  
PC standards [M-CH3] - [M+OAc] - 
18:0-22:6Δ4,7,10,13,16,19 PC 818 892 
16:0-18:1Δ9 PC 744 818 
18:1Δ9-0:0 PC 506 580 
 
MS/MS experiments 
The conditions for all MS/MS experiments were the same as for full scan experiments (Table 
9). Initially the collision energy (CE) was varied for all standards, and through several 
experiments a CE of 28V proved best for 18:0-22:6Δ4,7,10,13,16,19 PC and 16:0-18:1Δ9 PC. For 
the lysophospholipid, 18:1Δ9-0:0 PC, a CE of 25V provided fragment ions of high intensity 
where also the precursor ion was visible. Mass spectra of all standards are displayed in 
Appendix 12. A series of 10 runs of each of the PCs were run to establish that this method 
was reliable. Expected fragmentations of all PC standards are shown in the figures below. As 
seen from the spectra in Appendix 12 expected fragments described in 4.3. ESI-MS of lipids, 













Figure 14: Expected fragmentation 18:0-22:6Δ4,7,10,13,16,19 PC upon CID  





In 18:0-22:6Δ4,7,10,13,16,19 PC both fatty acid 18:0 and 22:6Δ4,7,10,13,16,19  was present. The 18:0 
fatty acid has a monoisotopic mass of 283.2637 Da, while 22:6Δ4,7,10,13,16,19  has a 
monoisotopic mass of 327.2324 Da. The fatty acid in sn-2 position, 22:6Δ4,7,10,13,16,19, will 
loose CO2 during fragmentation witch yields a fragment of 283. 2426 Da. To be able to 
establish which fatty acid signal that has the highest intensity it is essential to differentiate 
between the two. When the data format was set to centroid mode the signals 283.2426 (22:6) 
and 283.2637 (18:0) was displayed as one signal and thus information was lost. It is not 
possible to change the way the instrument generates centroid data during an acquisition and 
the data format was therefore changed to continuum where both signals were visible. This is 
shown in Appendix 12 and was also transferred to the MSE continuum experiments as well.  
The relative intensity of the two different fatty acids may be used to assign the position of the 
fatty acids on the glycerol backbone, as the fatty acid in sn-2 position have been thought to 
more likely undergo fragmentation and produce a higher intensity signal in the mass 
spectrometer. Only the data acquired in MS/MS continuum mode and MSE  mode could be 
used to investigate this. For 18:0-22:6Δ4,7,10,13,16,19 PC only data from MSE experiments were 
available for analysis. In a series of 6 runs the relative ratio between R2COO-/ R1COO- 
fragment ions were studied, and the results are displayed in Table 25. The ratio was stable in 







Figure 16: Expected fragmentation 18:1-0:0 PC upon CID 
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Table 25: MSE  experiments of 18:0-22:6Δ4,7,10,13,16,19 PC (CE 28V) and the ratio between  
R2COO-/ R1COO- fragment ions 










1 100 22 82 1,49 
2 100 25 76 1,64 
3 100 26 76 1,66 
4 100 24 79 1,57 
5 100 23 78 1,58 
6 100 24 82 1,51 
 
Also when mobile phase composition 3 was tested the R2COO-/ R1COO- ratio proved stable 
for 18:0-22:6Δ4,7,10,13,16,19 PC. The results of these experiments are displayed in Table 26.  
  
Table 26: MSE  experiments of 18:0-22:6Δ4,7,10,13,16,19 PC (CE 28V) and the ratio between  
R2COO-/ R1COO- fragment ions 










1 100 24 38 3,26 
2 100 24 36 3,44 
3 100 22 34 3,59 
4 100 26 36 3,50 
5 100 25 34 3,68 
6 100 24 38 3,26 
 
For 16:0-18:1Δ9 PC a series of 10 consecutive runs were performed and also in these 
experiments the ratio between the carboxylate anions proved stable. The results can be viewed 
in Appendix 13.  
These experiments showed a stable ratio between the fragments of the two fatty acids in sn-1 
and sn-2 position of PC compounds. Because recent studies had suggested that CID spectrum 
alone was not enough to reveal the regioisomerism and that the relative intensity of the 
carboxylate ions also could be influenced by the collision energy, experiments with different 
collision energies were set up. The experiments only had one parallel each, which is a 
limitation, but the results could be an indication of the effect the collision energy has on the 
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R2COO-/ R1COO- fragment ratio. As these experiments were performed when operating in 
centroid mode the data for 18:0-22:6Δ4,7,10,13,16,19 PC is not valid because of the inability to 
distinguish between the two different m/z 283 fragments. For 16:0-18:1Δ9 PC however the 
MS/MS centroid data revealed that there was a greater variation between R2COO-/ R1COO- 
ratio for the different collision energies than when the same collision energy was applied. 
This indicated that care are must be taken when using the carboxylate anion ratios of PCs to 
assign the position of the fatty acids on the glycerol backbone. The ratios for the different CEs 
are displayed in Table 27.  
 
Table 27: MS/MS experiments of 16:0-18:1Δ9 PC where the collision energy was varied to study the ratio 
between R2COO-/ R1COO- fragment ions 



















15 N/A N/A N/A N/A N/A N/A 
25 100 49 2,04 100 48 2,08 
28 100 46 2,17 100 61 1,64 
30 100 53 1,89 100 56 1,79 
32 100 45 2,22 100 69 1,45 





7.1.3. Analysis of phosphatidylethanolamine standards 
 
The phosphatidylethanolamine (PE) standards 16:0-18:1Δ9 PE and 16:0-0:0 PE from Avanti 
have also been used as a basis for development of optimal chromatography and MS methods. 
All PE standards were dissolved in ethanol and 0.1% ammonia solution (50:50). The research 
done one PE standards is less extensive than for the PC standards. The PE standards have 
been tested throughout the project with some of the more successful methods developed for 
PC standards. Full scan MS was used to find the precursor ions and MS/MS analysis to gain 
information on the fatty acid composition. 
 
Development of UPLC method for analysing phosphatidylethanolamine standards 
Mobile phase composition 2 
The gradient profile that was optimised for PC standards for analysis on the Acquity UPLC®  
BEH C18 VanGuard Pre-column was transferred to the PE standards. The gradient is 
displayed in Table 28.  
 
Table 28: Gradient profile used in analysis of PE standards (10 µg/ml) on Acquity  





Mobile phase A 
Water with 2% TEA 
Mobile phase B 









15 0.6 0 % 100%  
 
PE standards analysed on this column also resulted in chromatographic separation where the 
intensity of the precursor ion peaks were high and the peaks had little to no tailing. The PE 
standards did not display as much background noise as the PC standards analysed, and 
therefore produced better chromatograms that are displayed in Appendix 14.  
 
Mobile phase composition 3 
The standard 16:0-18:1Δ9 PE was analysed using Acquity UPLC BEH C18 50 mm column 
and mobile phase composition 3. The chromatography was improved, as the peak of the 
precursor ion was more symmetrical and had higher intensity and a shorter gradient profile 
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could be used. The gradient is displayed below in Table 29 and the chromatogram in 
Appendix 14.  
 
Table 29: 10 minute gradient profile used for analysis of 16:0-18:1Δ9 PE (10 µg/ml) with mobile  





Mobile phase A 
Acetonitrile/Water (40/60, v/v) 
with 10 mM Ammonium Acetate 
Mobile phase B 
Acetonitrile/Water (40/60, v/v) 










The PE standards were not tested with the longer Acquity UPLC®  BEH C18 150 mm 




MS method development for phosphatidylethanolamine standards 
 
To develop MS methods for identifying different structures in phospholipid samples both MS 
and MS/MS experiments of PE standards were set up. Full scan MS was used to find the 
precursor ions and MS/MS was used to gain information on the fatty acid components, and if 
possible their position on the glycerol backbone. Whenever MSE was utilized this information 
was gained during a single chromatographic run.  
 
Precursor ion detection 
The conditions for all full scan TOF-MS data were the same as in the preliminary experiments 
and are shown in Table 9. The initial experiments were performed using mobile phase 
composition 2 and from the full scan MS spectra the precursor ions for the two PE standards 
were detected.  These are summarised in Table 30. The dominant precursor ion was the 
deprotonated molecular ion [M-H]-.  
 
Table 30: Precursor ions detected for PE standards  
(10 µg/ml) using mobile phase composition 2.  
PE standards [M-H] - 
16:0-18:1Δ9 PE 716 
16:0-0:0 PE 452 
 
Changing to mobile phase composition 3 did not alter the detected precursor ion for PE as it 
did for PC standards. [M-H]- remained the dominant precursor ion as seen in Appendix 15.  
 
MS/MS experiments  
The conditions for all MS/MS experiments were the same as for full scan experiments (Table 
9). Initially the collision energy was varied for both standards and through several 
experiments a CE of 28V for 16:0-18:1Δ9 PE and a CE of 25V for 16:0-0:0 PE provided 
fragment ions of high intensity where also the precursor ion was visible. A series of 10 runs of 
each of the PE standards were run to establish that this method was reproducible. Expected 
fragmentation of both PE standards is shown in Figure 17 and Figure 18 below. As seen from 
the spectra in Appendix 16 expected fragments, as described in 4.3. ESI-MS of lipids, were 
visible. Some were only upon magnification.  
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Figure 17: Expected fragmentation of 16:0-18:1Δ9 PE upon CID. 














The relative intensity of the two different fatty acids may be used to assign the position of the 
fatty acids on the glycerol backbone. Only the data acquired in MS/MS continuum mode and 
MSE  mode could be used to investigate this and for the PE standards only 16:0-18:1Δ9 PE was 
analysed. In a series of 10 consecutive runs the relative ratio between R2COO-/ R1COO- 
fragment ions were studied, and the results are displayed below in Table 31.  
 
Table 31: MS/MS  experiments of 16:0-18:1Δ9 PE (CE 28V) and the ratio between  
R2COO-/ R1COO- fragment ions 
[M-H] - = 716 
Experiment Intensity of 







1 100 50 2,00 
2 100 51 1,96 
3 100 50 2,00 
4 100 48 2,08 
5 100 49 2,04 
6 100 50 2,00 
7 100 48 2,08 
8 100 50 2,00 
9 100 50 2,00 
10 100 51 1,96 
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In these experiments the ratio between the carboxylate anions proved stable, but because the 
relative intensity of the carboxylate ions also could be influenced by the collision energy, 
experiments with different CEs were set up. For 16:0-18:1Δ9 PE these experiments revealed 
that even though the CE was varied the R2COO-/ R1COO- ratio proved stabile. The 
experiments only had one parallel each, which is a limitation and care should be taken when 
using the carboxylate anion ratios of PEs to assign the position of the fatty acids on the 
glycerol backbone. The ratios for the different CEs are displayed in Table 32.  
 
Table 32: MS/MS experiments of 16:0-18:1Δ9 PE where the collision  
energy was varied to study the the ratio between R2COO-/ R1COO- fragment ions 











15 N/A N/A N/A 
25 100 51 1,96 
28 100 50 2,00 
30 100 51 1,96 
32 100 52 1,92 




7.2. Krill oil capsules analysed with UPLC-MS 
 
Two different brands of krill oil were analysed. To be able to analyse commercial krill oil 
capsules it is necessary to dissolve it in a media that is applicable to LC-MS instrumentation. 
The gradient profile used for all krill oil samples during dissolution experiments are 
illustrated in Table 15. This was all conducted on the Acquity UPLC VanGuard Pre-
column with mobile phase composition 2 using MSE technology. The krill oil capsules were 
cut open and dissolved in ethanol. The capsules needed approximately 12 minutes to reach a 
homogenous orange coloured solution. Before introducing the samples into the LC-MS 
system they were diluted. The strength of the krill solution was gradually increased to find the 
best but lowest concentration needed for analysis of the phospholipids. Concentrations from 
10 µg µg /ml to 1000 µg/ml were tested, and 1000 µg/ml was chosen for further analysis. The 
samples were diluted with a mixture of ethanol and MilliQ water or ethanol and 0.1% 
ammonia solution. The dissolving and dilution method that proved best for analysis is 
displayed below in Table 33. 
 
Table 33: Preparation of krill oil capsules prior to analysis.  
1. Cut open krill capsule. 
2. Dissolve in 100 ml Ethanol, while stirring  
at 200rpm for approximately 12 minutes. 
3. Dilute with pure MilliQ water to a concentration of 
1000 µg/ml. 
4. Filter with 0.25 mm filter. 
 
Development of UPLC method for analysing krill oil capsules 
The krill oil samples have been tested throughout the project with some of the more 
successful methods developed for PC and PE standards. 
 
Mobile phase composition 2 
These complex lipid samples were first analysed on the short Acquity UPLC®  BEH C18 
VanGuard Pre-column. The gradients tested resembled the optimal gradient for 
phospholipid standards, Table 16, and the best chromatography was achieved with the 




Table 34: Optimal gradient for analysing complex lipid samples on  





Mobile phase A 
Water with 2% TEA 
Mobile phase B 









15 0.6 0 % 100%  
 
The chromatogram is shown in Appendix 17. All peaks were broad and are likely to contain 
several different phospholipid compounds. Other gradients were also explored, but did not 
provide as good results, and are also displayed in Appendix 17.  
To achieve better separation of the lipids in the krill oil capsules the Acquity UPLC BEH 
C18 50 mm column was tested. The samples were first analysed using mobile phase 
composition 2 with 2% TEA and the gradient that proved to provide the best separation for 
krill oil on the 5mm pre-column (Table 34) was used. Because this proved to be a very 
complex mixture of lipids extended gradient profiles were tested and the flow decreased to 
0.5 ml/min. A 40-minute gradient with a slower increase of mobile phase B at the end was the 
one that provided the best chromatographic separation of compounds in the krill oil capsules. 
The gradient is displayed below and the chromatogram in Appendix 18. Other gradient 
profiles that were tested are also displayed in Appendix 18.  
 
Table 35: 40-minute gradient used to analyse Life krill oil capsules on the  





Mobile phase A 
Water with 2% TEA 
Mobile phase B 


















Mobile phase composition 3 
Using mobile phase composition 3 improved the chromatography when analysing krill oil 
capsules. The gradients that were developed for PC standards were transferred to these 
complex lipid samples. Both the 10-minute gradient (Table 18) and 30-minute gradient (Table 
19) were tested with the Acquity UPLC BEH C18 50 mm column and provided better base 
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Figure 19: Rimfrost krill oil (1000 µg/ml) analysed with mobile phase composition 3 on Acquity UPLC®  BEH C18 
column 150 mm using a 57 minute gradient. 
line separation and also more intense and symmetrical peaks. The 30-minute gradient 
separated the different lipid compounds to a greater extent and the chromatogram is displayed 
in Appendix 19. 
The optimal UPLC conditions for analysing PC standards, using the Acquity UPLC®  BEH 
C18 150 mm column, were also used for analysis of the krill oil samples. The gradient 
profiles developed for these experiments were based on the gradient that provided the best 
chromatographic results for the krill oil samples using mobile phase composition 2 (Table 
35). The gradients were extended and the starting conditions were experimented with. The 
optimal gradient when taking both chromatographic separation and time management into 
consideration proved to be a 57-minute gradient, which is displayed below in Table 36 with 
the corresponding chromatogram in Figure 19. 
 
Table 36: Optimal gradient for analysing Rimfrost krill oil capsules on the  





Mobile phase A 
Acetonitrile/Water (40/60, v/v) 
with 10 mM Ammonium Acetate 
Mobile phase B 
Acetonitrile/Water (40/60, v/v) 































There was improved separation of the compounds in the krill oil sample. The peaks in the 
chromatograms had a higher intensity and there were more base line separation. Other 
gradients that were tested are shown in Appendix 20 with corresponding chromatograms.  
 
MS method development for krill oil capsules 
 
All full scan MS and MS/MS experiments done with krill oil samples were executed using 
MSE technology taking advantage of the feature of not having to preselect precursor ions. The 
parameters for these MSE experiments are displayed in Table 37.  
 
Table 37: Parameters for MSE experiments.  
Conditions Parameters 
Capillary (kV) 0.6 
Sampling cone (V) 55 
Extraction cone 4 
Source temperature (C) 130 
Desolvation temperature (C) 350 
Cone gas (Lh-1) 20 
Desolvation gas (Lh-1) 800 
Low Mass (m/z) 100 
High mass (m/z) 1200 
Scan time (Sec.) 0.5 
Data Format Continuum 
Collision energy (V)  28 
 
The mass spectra and interpretation of the different compounds in the krill oil samples are 





7.3. AN raw extract analysed with UPLC-MS 
 
A raw extract with unknown phospholipid content was also analysed using the UPLC and MS 
methods that were developed for krill oil capsules. The methods that provided the best results 
were transferred to these experiments. There were two raw extracts where two different 
extraction methods were used. The raw extract was solid and was dissolved in the same way 
as the krill oil capsules following the steps in Table 33.  
 
Development of UPLC method for phospholipid raw extract 
Mobile phase composition 2  
 
The AN raw extract was first analysed on the Acquity UPLC BEH C18 50 mm column 
using mobile phase composition 2 with 2% TEA. The gradient profile that proved the best for 
krill oil capsules (Table 35) were used for the raw extract samples as well. Concentrations of 
1000 µg/ml, 2000 µg/ml and 4000 µg/ml were tested and the samples with the highest 
concentration provided results that could be used for analysis and interpretation. The 
chromatogram can be seen in Appendix 21. There are many similarities between the two 
different raw extracts and there were several peaks of high intensity, but they were all broad 
and not symmetrical. There was clearly more than one compound in each peak making it hard 
to identify the structures of the different lipids. 
 
Mobile phase composition 3  
 
Using mobile phase composition 3 improved the chromatography for the raw extracts. Both 
the 10-minute gradient (Table 18) and 30-minute gradient (Table 19) that were developed for 
PC standards and also used for analysis of the krill oil samples were tested with the Acquity 
UPLC BEH C18 50 mm column. Even with shorter gradients this provided better base line 
separation and also more intense peaks. The 30-minute gradient separated the different lipid 
compounds in the raw extracts to a greater extent and the chromatograms for both extraction 
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Figure 20: Phospholipid raw extract (4000 µg/ml) analysed with mobile phase composition 3 on Acquity 
UPLC®  BEH C18 column 150 mm using a 57 minute gradient. 
The optimal UPLC conditions for analysing PC standards and krill oil capsules, using the 
Acquity UPLC®  BEH C18 150 mm column, were also tested with raw extracts. All the 
different gradients that were tried for krill oil samples were also tried with the raw extracts 
and, as for the krill oil samples, the 57-minute gradient proved the best when considering both 















There was improved separation of the compounds in the raw extract sample as well. The 
peaks in the chromatograms had a higher intensity and there were more base line separation. 
Other gradients that were tested are shown in Appendix 23 with corresponding 
chromatograms.  
 
MS method development for phospholipid raw extract 
 
All full scan MS and MS/MS experiments done with raw extracts were executed using MSE 
technology taking advantage of the feature of not having to preselect precursor ions. The 
parameters for these MSE experiments were the same as for krill oil samples, and are 
displayed in Table 37. 
 
The mass spectra and interpretation of the different compounds in the raw extract samples are 
displayed in the results and discussion chapter.  
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8. Results and discussion  
8.1 Choice of methods 
 
The methods for analysing complex lipid samples were developed by testing different 
columns, mobile phases and gradient profiles.  
When utilizing the shorter columns separation was accomplished, but it was clear from the 
chromatograms that several compounds co-eluted and further separation was needed to more 
precisely identify the structures. The best result was achieved when the longest column was 
utilized, and ideally to gain even better separation of the compounds within the same time 
frame, an even longer column could have been employed.  
The different mobile phase compositions tested provided different opportunities for analysing 
both the standards and the more complex lipid mixtures. Using mobile phase composition 2, 
with methanol and TEA (Table 12), there was poor reproducibility. The results varied from 
day to day, even with the same conditions applied both for samples and instrumentation. Ion 
suppression occurred in some of the experiments, and most of the chromatographic peaks 
were broad and not ideal for further analysis. Mobile phase 3, consisting of acetonitrile, 
isopropanol and ammonium acetate (Table 17), greatly improved the chromatography of both 
standards and complex samples. It also allowed shorter gradients without compromising the 
chromatographic separation of the compounds in the krill and raw extract samples. Because of 
the increased separation this provided a better opportunity for identifying different lipid 
structures. Identifying phospholipid structures and assigning the position of the fatty acid 
components was achieved by studying full scan MS and MS/MS spectra. MSE technology was 
able to provide all the needed information in a single run and was therefore the optimal 
choice. In negative ESI mode information about the PL class and the fatty acid components 
were obtained. The position of the fatty acids on the glycerol backbone could be determined 
from studying the CID recorded spectra. Experiments with the PC and PE standards revealed 
that the relative ratio of the carboxylate anions could be used to assign the fatty acids to either 
the sn-1 or sn-2 position. For the two PC standards that had fatty acids attached in both sn-1 
and sn-2 position (18:0-22:6Δ4,7,10,13,16,19 PC and 16:0-18:1Δ9 PC), the relative ratio between 
R2COO-/ R1COO- fragment ions were studied in a series of consecutive runs. For 18:0-
22:6Δ4,7,10,13,16,19 PC a series of 6 consecutive runs were performed with both mobile phase 
composition 2 and mobile phase composition 3. In these experiments the CE was held 
constant at 28V and for both mobile phases the ratio proved stabile. For 16:0-18:1Δ9 PC a 
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series of 10 consecutive runs were performed using mobile phase composition 3. The R2COO-
/ R1COO- ratio proved stabile also in these experiments. Because it has been suggested that 
the relative intensity of the carboxylate ions also could be influenced by the collision energy, 
experiments with different collision energies were set up. The results revealed that there was a 
greater variation between R2COO-/ R1COO- ratio for the different collision energies than 
when the same collision energy was applied. Because these experiments only had one parallel 
more research is needed to properly establish the effect of the collision energy and also to 
investigate degree of saturation and the total chain length.  
When the same experiments were performed with the 16:0-18:1Δ9 PE standard, a series of 10 
consecutive runs proved that the relative ratio between R2COO-/ R1COO- fragment ions was 
stable when a CE of 28V was applied. Experiments were the CE was varied also provided 
stabile results. As with the PC standard these experiments only had one parallel each, which is 
a limitation and care should be taken when using the carboxylate anion ratios of PEs to assign 
the position of the fatty acids on the glycerol backbone. 
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The MS (1) and MS/MS (2) chromatograms of Rimfrost krill oil capsules revealed that this 
was a complex mixture of compounds. When taking both chromatographic separation and 
time management into consideration, the 57-minute gradient provided the best separation of 
compounds. Several peaks were of high intensity and there was adequate base line separation. 
There were two distinct areas of peaks in the chromatogram. The first half was the area where 
free fatty acids and the lysoPLs eluted and the second half where the less polar phospholipids 
and triglycerides eluted. Below are the magnified chromatograms of each of the two distinct 
areas (Figure 22 and Figure 23). The area between 28 and 32 minutes is not magnified, as this 
does not contain peaks of high intensity or of interest. The numbered peaks are the ones that 
were possible to interpret as their intensity was high enough and the chromatographic 
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Figure 21: Full scan MS (1) and MS/MS (2) acquired using MSE. Analysis of Rimfrost krill oil capsules  
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Figure 22: Magnified full scan MS (1) and MS/MS (2) of Rimfrost krill oil capsules (1000 µg/ml) 
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Figure 24: MS (1) and MS/MS (2) spectra for the chromatographic peak 1  
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Full scan MS 
Figure 25: Full scan MS and MS/MS chromatograms along with the 
chromatograms for the individual m/z signals. 
 













From the MS and the MS/MS spectra one compound could be identified. The signal at m/z 
526 was likely to be a PC as an acetate adduct at m/z 600 was also observed. The dominant 
fatty acid component was at m/z 301 (20:5Δ5,8,11,14,17), with the corresponding loss of CO2 to 
yield a m/z 257 signal. The signal at m/z 224 also indicated that this was a PC as this is a class 
specific fragment. To further confirm the compound, the chromatograms for the individual 
peaks in the spectra were studied. Similar retention time and peak shape indicated that the 
elements originated from the same phospholipid. Figure 25 shows that the m/z 301 signal 
showed a similar retention time and peak shape as the m/z 526 and m/z 600, which confirmed 













The relatively short retention time and [M-CH3]- at m/z 526 indicated that this was a 
lysophospholipid with only one fatty acid attached. It was not possible from the data obtained 
to identify the position of the fatty acid. Since most lysophospholipids have the fatty acid 
attached in sn-1 position the compound was drawn in accordance with this. Table 38 
summarizes the elements of the compound identified in peak 1. 
 
Table 38: Summary of the elements of the compound identified in peak 1 
 [M+OAc] - [M-CH3] - Fatty acid components  




















Figure 26: MS (1) and MS/MS (2) spectra for the chromatographic peak 2 
m/z
































From the MS and the MS/MS spectra one compound could be identified. The signal at m/z 
480 was likely to be a PC as an acetate adduct at m/z 554 also was observed. The class 
specific fragment at m/z 224 also indicated that this was a PC. The dominant fatty acid 
component was at m/z 255 (16:0). The structure elucidation was performed as for the lysoPC 
in peak 1. The relatively short retention and [M-CH3]- at m/z 480 indicated that this was a 
lysophospholipid with only one fatty acid attached. It was not possible from the data obtained 
to identify the position of the fatty acid. Since most lysophospholipids have the fatty acid 
attached in sn-1 position the compound was drawn in accordance with this. Table 39 
summarizes the elements of the compounds identified in peak 2.  
 
Table 39: Summary of the elements of the compound identified in peak 2 
 [M+OAc] - [M-CH3] - Fatty acid components  



















Figure 27: MS (1) and MS/MS (2) spectra for the chromatographic peak 3 
m/z



































From the MS and the MS/MS spectra one compound could be identified. The signal at m/z 
506 was likely to be a PC as an acetate adduct at m/z 580 also was observed. The class 
specific fragment at m/z 224 also indicated that this was a PC. The dominant fatty acid 
component was the m/z 281 (18:1) signal. The structure elucidation was performed as for the 
lysoPC in peak 1 and for the fatty acid component 18:1 it is was not possible to identify where 
the double bond was situated. Table 47 summarizes the elements of the compounds identified 
in peak 10.  Table 40 summarizes the elements of the compounds identified in peak 3.  
 
Table 40: Summary of the elements of the compound identified in peak 3 
 [M+OAc] - [M-CH3] - Fatty acid components  






















From the MS and the MS/MS spectra of peak 4 one compound could be identified. This peak 
contained all the same elements as peak 3, the only difference being the retention time. This 
peak eluted 0.12 minutes later. One possible explanation could be that the compound contains 
the same PC backbone and fatty, acid the only difference being the position of the fatty acid. 
For peak 3 and 4 it was not possible to determine if the fatty acid was situated in sn-1 or sn-2 
position. Table 41 summarizes the elements of the compounds identified in peak 4. 
 
Table 41: Summary of the elements of the compound identified in peak 4 
 [M+OAc] - [M-CH3] - Fatty acid components  

































































Figure 29: MS (1) and MS/MS (2) spectra for the chromatographic peak 5  












From the MS and the MS/MS spectra two compounds could be identified. The  
signals at m/z 710 and m/z 810 are likely to be two different PCs. In the MS spectra they both 
form acetate-adducts [M+OAc]-, at m/z 784 and m/z 884 respectively. The dominant fatty acid 
component was at m/z 301(20:5Δ5,8,11,14,17), with the corresponding loss of CO2 to yield a m/z 
257 signal. To gain more information on the structure of the compounds the chromatograms 
















35.70 35.75 35.80 35.85 35.90 35.95 36.00 36.05 36.10 36.15
%
1
35.70 35.75 35.80 35.85 35.90 35.95 36.00 36.05 36.10 36.15
%
1
35.70 35.75 35.80 35.85 35.90 35.95 36.00 36.05 36.10 36.15
%
4
35.70 35.75 35.80 35.85 35.90 35.95 36.00 36.05 36.10 36.15
%
1
35.70 35.75 35.80 35.85 35.90 35.95 36.00 36.05 36.10 36.15
%
3
35.70 35.75 35.80 35.85 35.90 35.95 36.00 36.05 36.10 36.15
%
5

































35.70 35.75 35.80 35.85 35.90 35.95 36.00 36.05 36.10 36.15
%
1
35.70 35.75 35.80 35.85 35.90 35.95 36.00 36.05 36.10 36.15
%
1
35.70 35.75 35.80 35.85 35.90 35.95 36.00 36.05 36.10 36.15
%
0




35.70 35.75 35.80 35.85 35.90 35.95 36.00 36.05 36.10 36.15
%
1




























Full scan MS 
Figur 30: Full scan MS and MS/MS chromatograms along with the chromatograms for 
the individual m/z signals. 
 62 
As seen from Figure 31 the [M-CH3]- at m/z 884, m/z 810 and m/z 301 co-eluted. This 
indicated that they came from the same phospholipid where the fatty acid 20:5Δ5,8,11,14,17 was 
attached both in sn-1 and sn-2 position. This also explains the high intensity of this signal.   
The assumed [M-CH3]- at m/z 710 had a lower intensity and consequently so had the 
corresponding fatty acid components. This PC compound contained m/z 227 (14:0) and m/z 
275 (18:4). For the fatty acid 18:4 it is was not possible to identify where the double bonds 
were situated. This compound is drawn with the m/z 275 (18:4) in sn-2 position and m/z 227 
(14:0) in sn-1 position. This is based on the ratio of the carboxylate anions, where the loss of 
the fatty acid in sn-2 position would be more likely to occur and thus yield a higher signal. 
Throughout the thesis this has been used to assign the positions of the fatty acids, as 
experiments performed with PC and PE standards proved that on this instrument using the 
optimised CE in the collision cell, the R2COO-/ R1COO- ratios were stable. 
The described method for identifying compounds in this peak was utilized in structural 
elucidation of all chromatographic peaks that partly co-eluted. Using the MSE feature to 
identify compounds is not possible if the peaks in the chromatogram completely co-elute, a 
small difference in elution time is required. It would be possible to identify structural 
elements but not the complete compound. This could be resolved by conducting MS/MS 
experiments of all single compounds, but this will be very time consuming compared with the 
MSE method. Table 42 summarizes the elements of the compounds identified in peak 5.  
Table 42: Summary of the elements of compounds identified in peak 5 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 884 m/z 810 






Compound  2 m/z 784 m/z 710  m/z 227 (14:0) 








































Figure 31: MS (1) and MS/MS (2) spectra for the chromatographic peak 6 












From the MS spectra (1) and the MS/MS spectra (2) two compounds could be identified. The 
signals at m/z 736 and m/z 836 are likely to be two different PCs. In the full scan MS spectra 
they both form acetate-adducts [M+OAc]-, at m/z 810 and m/z 910 respectively. The dominant 
fatty acid component was at m/z 301(20:5Δ5,8,11,14,17), with the corresponding loss of CO2 to 
yield a m/z 257 signal. Other fatty acid components observed were m/z 227 (14:0) and m/z 
327 (22:6Δ4,7,10,13,16,19). The m/z at 283 corresponds to the loss of CO2 to from m/z 327. The 
structure elucidation was performed as for the PLs in peak 5, but this peak was more 
complicated as the m/z 301 was present in both compounds. The chromatograms for the 
individual peaks are shown below.  
Figure 32 shows that the [M-CH3]- at m/z 736 had a similar retention time and peak shape as 
the m/z 227 signal. The m/z 810 signal also correlated with this. The chromatographic peak 
for the fatty acid with m/z 301 showed a similar retention time, but the peak shape indicated 
two partly overlapping peaks. This indicated that m/z 301 was part of both phospholipids, 
which also explains the high intensity of the signal. The [M-CH3]- at m/z 836 had a similar 
retention time and peak shape as the m/z 910 signal, as well as the m/z 301 and m/z 327 signal. 
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Figure 32: Chromatograms showing full scan MS and MS/MS experiment, in addition to the 















It is assumed that the relative intensity of the m/z 301 fragment from m/z 736 and m/z 836 
signal is similar to the integrated ratio between m/z 736 and m/z 836 themselves. When the 
m/z 736 and m/z 836 were integrated this showed a 64:36 ratio. For compound 1 the relative 
intensity of m/z 301 (20:5Δ5,8,11,14,17) was 68% when the signal intensity for m/z 257 was 
added. The division of the m/z 257 was done similarly to m/z 301. For m/z 227 (14:0) the 
relative intensity was calculated to be 29%, and therefor this fatty acid was determined to be 
in sn-1 position. 
This was used to assign the fatty acids of the PC based on the R2COO-/ R1COO- ratio. 
Assigning the sn-1 and sn-2 positions for compound 2 was more challenging. The relative 
intensity of m/z 301 (20:5Δ5,8,11,14,17) was 38% when the signal intensity of m/z 257 was 
added. The relative intensity of m/z 327 (22:6Δ4,7,10,13,16,19) was approximately 33% when the 
intensity of fragment m/z 283 was added. Because the ratio between the carboxylate anions 
was quite similar, assigning the position of the fatty acids based on this was more uncertain. 
To confirm the positions of the fatty acids experiments with standards should be performed. 




Table 43: Summary of the elements of compounds identified in peak 6 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 810 m/z 736 m/z 227 (14:0) 






Compound  2 m/z 910 m/z 836 m/z 327 (22:6Δ4,7,10,13,16,19) 





































Figure 33: MS (1) and MS/MS (2) spectra for the chromatographic peak 7 












From the MS and the MS/MS spectra one compound could be identified. The signal at m/z 
738 is likely to be a PC as an acetate adduct at m/z 812 also could be observed. Four different 
fatty acid components were identified where m/z 275 (18:4) was the dominant one.  
For the fatty acid 18:4 it is was not possible to identify where the double bonds were situated. 
The structure elucidation was performed as for the PLs in peak 5. Other visible elements such 
as the fatty acid components m/z 327 (22:6Δ4,7,10,13,16,19) and m/z 301 (20:5Δ5,8,11,14,17) did not 
co-elute with peak 7 and is assumed to come from another compound. From the late retention 
time this could originate from a triglyceride, as these compounds tend to elute at similar times 
as PLs and thus the chromatographic peaks may overlap. Table 44 summarizes the elements 
of the compounds identified in peak 7. 
 
Table 44: Summary of the elements of the compound identified in peak 7 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 812 m/z 738 m/z 255 (16:0) 














































Figure 34: MS (1) and MS/MS (2) spectra for the chromatographic peak 8  














From the MS and the MS/MS spectra one compound could be identified. The signal at m/z 
764 is likely to be a PC as an acetate adduct at m/z 838 also could be observed. Two different 
fatty acid components were identified where m/z 301 (20:5Δ5,8,11,14,17) had a higher intensity 
than m/z 255 (16:0). The fragment at m/z 257 results from 20:5Δ5,8,11,14,17 loosing CO2 during 
fragmentation. The structure elucidation was performed as for the PLs in peak 5. Table 45 
summarizes the elements of the compounds identified in peak 8.   
 
Table 45: Summary of the elements of the compound identified in peak 8 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 838 m/z 764 m/z 255 (16:0) 

















































Figure 35: MS (1) and MS/MS (2) spectra for the chromatographic peak 9 












From the MS spectra (1) and the MS/MS spectra (2) one compounds could be identified. The 
signals at m/z 790 was likely to be a PC as in the full scan MS spectra an acetate-adduct 
[M+OAc]- at m/z 864 was observed. There were four different fatty acid fragments observed, 
m/z 327 (22:6Δ4,7,10,13,16,19), m/z 255 (16:0), m/z 301 (20:5Δ5,8,11,14,17) and m/z 281 (18:1), 
where the two first dominated. The structure elucidation was performed as for the PLs in peak 
5. The signals at m/z 301 and m/z 281 had low intensity compared to the other fatty acid 
components and could possibly originate from a compound where the parent ion is not visible 
because the signal is too low. When the chromatography for the individual peaks were 
compared m/z 301 and m/z 281 eluted later than the three other signals and were therefore 
likely to be part of partly overlapping peaks as seen from the full MS and MS/MS spectra in 
Figure 23. Table 46 summarizes the elements of the compound identified in peak 9.   
 
Table 46: Summary of the elements of the compound identified in peak 9 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 864 m/z 790 m/z 255 (16:0) 
































From the MS and the MS/MS spectra one compound could be identified. The signal at m/z 
744 is likely to be a PC as an acetate adduct at m/z 818 also could be observed. Two different 
fatty acid components were identified, m/z 255 16:0) and m/z 281 (18:1), where the latter had 
the highest intensity. The structure elucidation was performed as for the PLs in peak 5. For 
the fatty acid component 18:1 it is was not possible to identify where the double bond was 
situated. Table 47 summarizes the elements of the compounds identified in peak 10.   
 
Table 47: Summary of the elements of the compound identified in peak 10 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 818 m/z 744 m/z 255 (16:0) 














































Figure 36: MS (1) and MS/MS (2) spectra for the chromatographic peak 10  
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m/z
































Figure 37: MS (1) and MS/MS (2) spectra for the chromatographic peak 11 












From the MS and the MS/MS spectra one compound could be identified. The signal at m/z 
846 is likely to be a PC as an acetate adduct at m/z 920 also could be observed. Two different 
fatty acid components were identified, m/z 337 (22:1) and m/z 301 (20:5Δ5,8,11,14,17), where the 
latter had the highest intensity. The structure elucidation was performed as for the PLs in peak 
5. For the fatty acid component 22:1 it is was not possible to identify where the double bond 
was situated. Other observed ions such as m/z 992 and m/z 1092 eluted later than the other 
three components. Upon magnification the chromatogram showed that this peak was 
asymmetrical and most likely contained two overlapping peaks. The other ions were therefore 
likely to be part of other compound(s) that are not likely to be phospholipids.  Table 48 
summarizes the elements of the compounds identified in peak 11.   
 
Table 48: Summary of the elements of the compound identified in peak 11 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 920 m/z 846 m/z 337 (22:1) 
































The MS (1) and MS/MS (2) chromatograms of Life krill oil capsules also proved to be a 
complex mixture of compounds. Similarly to the Rimfrost krill oil capsules the 57-minute 
gradient provided the best separation of compounds when taking both chromatographic 
separation and time management into consideration. Several peaks were of high intensity and 
upon comparison the chromatograms proved very similar. This chromatogram also had two 
distinct areas of peaks where in the first half the free fatty acids and the lysoPLs were 
detected and in the second part the less polar phospholipids and triglycerides were detected. 
When studying the individual mass spectra of the most intense peaks it was found that the 
compounds detected were very similar and when identifying PL structures the same 
compounds were observed. For some of the less intense peaks small differences were noticed 
but the signals were not high enough to be analysed. 
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Figure 38: MS (1) and MS/MS (2) chromatogram for Life krill oil capsules.  
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Figure  39: Full scan MS (1) and MS/MS (2) spectra acquired using MSE. Analysis of raw extract AN1 
(4000µg(ml) using Acquity UPLC®  BEH C18 150 mm column and mobile phase composition 3 with a 
57-minute gradient profile.  


















The MS (1) and MS/MS (2) chromatograms of the phospholipid raw extract proved that this 
was a complex mixture of compounds. As for the two other complex lipid samples the 57-
minute gradient provided the best separation of compounds. Several peaks were of high 
intensity and suited for structure determination of compounds. The two distinct areas of peaks 
that were observed for the previous krill samples were also observed here. Below are the 
magnified chromatograms of each of the two distinct areas where the free fatty acids and 
lysoPLs were detected and the area where the phospholipids were detected. The area between 
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Figure 41: Magnified full scan MS (1) and MS/MS (2) of raw extract (4000µg/ml). 
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Figure 42: MS and MS/MS spectra for the chromatographic peak 1 













From the MS (1) and the MS/MS (2) spectra one compound could be identified. The signal at 
m/z 480 was likely to be a PC as an acetate adduct at m/z 554 also was observed. The 
dominant fatty acid component was at m/z 255 (16:0). The structure elucidation was 
performed as for the lysoPC in peak 1 of the Rimfrost krill oil capsules. As seen from Figure 
40, this peak eluted early in the chromatogram. This combined with a [M-CH3]- at m/z 554 
indicated that this was a lysophospholipid with only one fatty acid attached. It was not 
possible from the data obtained to identify the position of the fatty acid. As with the previous 
lysoPLs the compound has been drawn with the fatty acid attached in sn-1 position. Table 49 
summarizes the elements of the compounds identified in peak 1. 
 
Table 49: Summary of the elements of the compound identified in peak 1 
 [M+OAc] - [M-CH3] - Fatty acid components  



























From the MS spectra (1) and the MS/MS spectra (2) two compounds could be identified. The 
signals at m/z 736 and m/z 836 are likely to be two different PCs. In the full scan MS spectra 
they both form acetate-adducts [M+OAc]-, at m/z 810 and m/z 910 respectively. The dominant 
fatty acid component was at m/z 301(20:5Δ5,8,11,14,17), with the corresponding loss of CO2 to 
yield a m/z 257 signal. The signal at m/z 227 (14:0) and m/z 327 (22:6Δ4,7,10,13,16,19) had similar 
intensities. The mass spectra revealed that this peak contains the same compounds as the ones 
observed in peak 6 for the Rimfrost krill oil capsules. The retention times for the peaks are 
also quite similar, at 36.90 minutes for the raw extract and 37.20 minutes for the krill oil 
sample. The structure elucidation was performed as for the PLs in peak 6. Also here the 
occurrence of m/z 301 (20:5Δ5,8,11,14,17) in both peaks made the assigning of the fatty acid 
position harder. When both m/z 736 and m/z 836 were integrated the relative ratio between 
them proved to be 41:59. For compound 1 the relative intensity of m/z 301 (20:5Δ5,8,11,14,17)  
was 43,9% when the intensity of m/z 257 was added, while it for m/z 227 (14:0) was 20%. 
This was used to assign the fatty acids of the PC based on the R2COO-/ R1COO- ratio. For 
compound 2 the relative intensity of m/z 301 (20:5Δ5,8,11,14,17) was 63.1%, while the relative 
intensity of m/z 327 (22:6Δ4,7,10,13,16,19) was approximately 35% when the intensity of 
fragment m/z 283 was added. This was used to assign the fatty acids based on the R2COO-/ 
R1COO- ratio. Table 50 summarizes the elements of the compounds identified in peak 2.  
 
  
Figure 43: MS and MS/MS spectra for the chromatographic peak 2  
m/z



































Table 50: Summary of the elements of compounds identified in peak 2 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 810 m/z 736 m/z 227 (14:0) 






Compound 2 m/z 910 m/z 836 m/z 327 (22:6Δ4,7,10,13,16,19) 







































Figure 44: MS (1) and MS/MS (2) spectra for the chromatographic peak 3 













From the MS and the MS/MS spectra two compounds could be identified. The signals at m/z 
762 and m/z 812 are likely to be two different PCs. In the MS spectra they both form acetate-
adducts [M+OAc]-, at m/z 836 and m/z 886 respectively. Four different fatty acid components 
were identified where m/z 301 (20:5Δ5,8,11,14,17) and m/z 253 (16:1) were the dominating ones 
and the m/z at 257 were the fragment from m/z 301 loosing CO2. For the fatty acid component 
16:1 it is was not possible to identify where the double bond was situated. There were two 
possible combinations of fatty acids that could be present in the phospholipid that 
corresponded to the [M-CH3]- at m/z 762. Both m/z 301 and 253, and m/z 327  
(22:6Δ4,7,10,13,16,19) and m/z 227 (14:0) add up to m/z 762 and to confirm the compound the 
chromatograms for the individual peaks in the spectra were studied. These chromatograms are 

























From the chromatograms it was revealed that m/z 762 had similar retention time and peak 
shape as the m/z 301 and m/z 253 signals, which indicated that the elements originate from the 
same phospholipid. The m/z 327 and m/z 227 signal did not co-elute with the [M-CH3]- at m/z 
762 as seen in Figure 46 and this made it possible to identify the different compounds.  
For the [M-CH3]- at m/z 812 the studies of the individual chromatograms showed that m/z 327 
and m/z 227 had similar retention times and peaks shapes. For these three m/z signals the 
intensity were lower and the m/z 227 was only visible upon magnification. This confirmed 
that there were two compounds included in peak 3, where [M-CH3]- at m/z 762 with the fatty 
acid components m/z 301 and m/z 253 was the dominant phospholipid. For the fatty acid 16:1 
it is was not possible to identify where the double bonds were situated. Table 51 summarizes 
the elements of the compounds identified in peak 3. 
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Full scan MS 
Figure 45: Chromatograms showing full scan MS and MS/MS experiment., in addition to the 
individual chromatograms for single signals. 
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Table 51: Summary of the elements of compounds identified in peak 3 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 836 m/z 762 m/z 253 (16:1) 






Compound  2 m/z 886 m/z 812 m/z 227 (14:0) 















































Figure 46: MS (1) and MS/MS (2) spectra for the chromatographic peak 4  














From the MS and the MS/MS spectra one compound could be identified. The signals at m/z 
762 and m/z 862 are likely to be two different PCs. In the MS spectra they both form acetate-
adducts [M+OAc]-, at m/z 836 and m/z 936 respectively. Four different fatty acid components 
were identified where m/z 327 (22:6Δ4,7,10,13,16,19) and m/z 227 (14:0) were the dominating 
ones, while the m/z 301 and m/z 253 (16:1) signal were of lower intensities. The m/z at 283 
was the fragment from m/z 327 loosing CO2 during fragmentation. There were two possible 
combinations of fatty acids that could be present in the phospholipid that corresponded to the 
[M-CH3]- at m/z 762. Both m/z 327 and 227, and m/z 301 and 253 adds up to m/z 762. The 
structure elucidation was performed as for the PLs in peak 3 on the raw extract. The signals at 
m/z 301 and m/z 253 could originate from a compound where the parent ion is not visible 
because the signal is too low. There were signals in the spectra to indicate that there was a PC 
compound with a [M-CH3]- at m/z 862 because it also formed an acetate adduct. None of the 
observed fatty acid components however corresponded with this. Table 52 summarizes the 




Table 52: Summary of the elements of the compound identified in peak 4 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 836 m/z 762 m/z 227 (14:0) 

















































Figure 47: MS (1) and MS/MS (2) spectra for the chromatographic peak 5  
 












From the MS and the MS/MS spectra one compounds could be identified. The signal at m/z 
788 is likely to be a PC as an acetate adduct at m/z 862 also could be observed. Six different 
fatty acid components were identified where m/z 327 (22:6Δ4,7,10,13,16,19) and m/z 253 (16:1) 
were the dominating ones. The peak at m/z 283 resulted from the fatty acid at m/z 327 loosing 
CO2 during fragmentation. Other observed elements such as the fatty acid components m/z 
227 (14:0), m/z 255 (16:0), m/z 275 (18:4) and m/z 301 (20:5Δ5,8,11,14,17) as well as the signals 
m/z 738 and m/z 762. Some of these signals had low intensities and were only visible upon 
magnification. This made identification of the compounds difficult. The structure elucidation 
was performed as for the PLs in peak 3 in the raw extract. 
One possible PC compound could be a [M-CH3]- at m/z 738 with the fatty acids m/z 255 
(16:0) and m/z 275 (18:4) attached. The retention times for these signals were similar but the 
peak shapes only party resembled each other, which made it hard to draw conclusions 
regarding the compound. As peak 5 was not entirely symmetrical it is likely that it comprises 




Table 53: Summary of the elements of the compound identified in peak 5 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 862 m/z 788 m/z 253 (16:1) 





































Figure 48: MS (1) and MS/MS (2) spectra for the chromatographic peak 6 
 












From the MS and the MS/MS spectra one compound could be identified. The signal at m/z 
764 is likely to be a PC as an acetate adduct at m/z 838 also could be observed. The different 
fatty acid components were identified where were m/z 301 (20:5Δ5,8,11,14,17) and 
m/z 255 (16:0) were the dominating ones. The peak at m/z 257 resulted from the fatty acid at 
m/z 327 loosing CO2 during fragmentation. Other observed elements were the fatty acid 
component m/z 327 (22:6Δ4,7,10,13,16,19). The structure elucidation was performed as for the 
PLs in peak 3 of the raw extract. Table 54 summarizes the elements of the compounds 
identified in peak 6. 
 
Table 54: Summary of the elements of the compound identified in peak 6 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 838 m/z 764 m/z 255 (16:0) 





































Figure 49: MS (1) and MS/MS (2) spectra for the chromatographic peak 7  
 













From the MS and the MS/MS spectra one compound could be identified. The signal at m/z 
790 is likely to be a PC as an acetate adduct at m/z 864 also could be observed. Two different 
fatty acid components, m/z 327 (22:6Δ4,7,10,13,16,19) and m/z 255 (16:0), were identified. The 
peak at m/z 283 resulted from the fatty acid at m/z 327 loosing CO2 during fragmentation.  
The structure elucidation was performed as for the PLs in peak 3 in the raw extract and Table 
55 summarizes the elements of the compounds identified in peak 7. 
 
Table 55: Summary of the elements of the compound identified in peak 6 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 864 m/z 790 m/z 255 (16:0) 





















































Figure 50: MS (1) and MS/MS (2) spectra for the chromatographic peak 8 












From the MS and the MS/MS spectra one compounds could be identified. The signal at m/z 
818 was likely to be a PC as an acetate adduct [M+OAc]- at and m/z 892 was also observed. 
Several fatty acids were identified where m/z 327 (22:6Δ4,7,10,13,16,19) and m/z 283 (18:0) 
dominated. Upon magnification it was visible that the m/z 283 signal represented two 
different signals, where one came from m/z 327 loosing CO2 upon fragmentation to yield 
283.2351 and the other was the fatty acid 18:0 with a m/z 283.2557. The structure elucidation 
was performed as for the PLs in peak 3 in the raw extract. There were a lot of other signals in 
these spectra that did not co-elute with the identified compound. As seen from the 
chromatogram (Figure 41) this peak was not well separated from other peaks and thus 
interfering signals will appear. Table 56 summarize the elements of the compound identified 
in peak 8. 
 
Table 56: Summary of the elements of the compound identified in peak 8 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 892 m/z 818 m/z 283 (18:0)  











































Figure 51: MS (1) and MS/MS (2) spectra for the chromatographic peak 9 













From the MS and the MS/MS spectra one compound could be identified. The signal at m/z 
744 was likely to be a PC as an acetate adduct [M+OAc]- at and m/z 818 was also observed. 
Three fatty acids were identified where m/z 281 (18:1) and m/ 255 (16:0) dominated. A m/z 
327 (22:6Δ4,7,10,13,16,19)  signal was also seen, and the corresponding m/z 283 from the loss of 
CO2. The structure elucidation was performed as for the PLs in peak 3 in the raw extract.  
As with the previous peak the chromatographic separation was not optimal and resulted in 
interfering signals from nearby peaks. Table 57 summarize the elements of the compound 
identified in peak 9. 
 
Table 57: Summary of the elements of the compound identified in peak 9 
 [M+OAc] - [M-CH3] - Fatty acid components  
Compound 1 m/z 818 m/z 744 m/z 255 (16:0) 
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Figure 52: Peaks in the chromatogram of Rimfrost krill oil capsules (1000 µg/ml) that contained the 
essential fatty acids EPA and DHA  
Time
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8.5. Evaluation of DHA and EPA content  
 
As previously mentioned the main ingredients of marine oils, that the manufacturers make 
health claims about, are the essential fatty acids eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). As seen from the EU legislation there are requirements to the 
contents of the products if the producers are to make claims about them, and therefor it was 
interesting to see weather the main detected ingredients in krill oil capsules and raw extract 
were found to be EPA and DHA. In Figure 52 the chromatographic peaks containing EPA 



















The EPA and DHA containing peaks were labelled in the full scan MS chromatogram as the 
intensity of the fragment peaks in the MS/MS chromatogram can vary. This showed that some 
of the most intense peaks contained either one or both essential fatty acids. A high proportion 
of the overall content contained EPA and/or DHA. The krill oil also contained many 
phospholipid compounds that had other fatty acids attached, in addition to several peaks that 
were only of high intensity in the full scan MS spectra. Because the method was optimised for 





chromatogram was peak 8, which contained EPA. Whenever EPA was observed, the essential 
fatty acid was situated in sn-2 position. One of the EPAs detected were in the form of lysoPC. 
When DHA was detected in the peaks it was attached in sn-1 position for peak 6 and in sn-2 
position for peak 9. The krill oil capsules and the raw extract chromatograms were not 
directly comparable because of the difference in concentration, however the basic compounds 
of the two products were proved to be comparable. Because the samples were analysed on the 
same instrument and under the same conditions, a similar degree of ionisation was achieved 













The full scan MS chromatogram of the raw extract displayed in Figure 53 showed that, 
compared to the krill oil sample, a higher proportion of the total content contained EPA 
and/or DHA. None of the peaks in the lysoPL region contained either of the essential fatty 
acids, however in the PL region most of the dominant peaks detected contained EPA or DHA. 
In the two most dominant peaks, peak 6 and peak 7, both the essential fatty acids were 
detected. Whenever EPA was identified it was attached in the sn-2 position, the exception 
being peak 3. The same trend was observed for DHA, where in all but one compound, the 
essential fatty acid was attached in sn-2 position. The analyses revealed that the raw extract 
had a relatively higher EPA and DHA content than the krill oil capsules. This showed that the 
methods developed by the manufacturer AN was successful in enriching the phospholipids 
with EPA and DHA. As the raw extract was extracted from other sources than krill oil this 
shows that in addition to krill there are also other marine sources that have a high content of 
the essential fatty acids EPA and DHA.  
Figure 53: Peaks in the chromatogram of phospholipid raw extract (4000µg/ml) that contained the essential 
fatty acids EPA and DHA 
Time
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In these experiments only phosphatidylcholine species were identified, and from the 
knowledge of krill oil and the raw extract content this was also expected.  
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9. Conclusion and future prospects  
 
A novel UPLC and MS method was developed for analysing phospholipid standards and 
complex phospholipid samples. The methods developed allowed for identification and 
structural elucidation of different PL species and by utilizing MSE technology, rapid 
qualitative analyses of complex lipid samples were made possible. A mobile phase consisting 
of acetonitrile, isopropanol and water with ammonium acetate provided the best reversed 
phase chromatographic separation when analysed with a narrow bore (1mm) 150mm C18 
column. By using UPLC-MS it was confirmed that a high proportion of the total content of 
commercial marine oils contained the essential fatty acids EPA and DHA. The study also 
showed that the two different brands of krill oil capsules had very similar content. There was 
greater variation in the fatty acid species of the krill oil than of the raw extract, and the raw 
extract seems successfully enriched with EPA and DHA.  
Few studies have been done on commercial phospholipid samples such as krill oil and raw 
extract intended for commercial use. The present study is a contribution to the evaluation of 
marine oils used as dietary supplements and weather the content of the supplements match the 
labelled ingredients.  
 
The next step of the method development would be to use the established methods to analyse 
more PLs standards and also other more complicated lipid samples. Another natural step 
would be to verify the regioisomerism by conducting experiments with phospholipases, and 
particularly phospholipase A2, for both standards and complex lipid mixtures. To gain more 
knowledge about dissolution and absorption of phospholipids the use an in vitro dissolution 
testing system, such as a Sotax, to imitate the conditions of the intestine would be beneficial. 
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Appx. Figure 2: E80 from Lipoid analysed on Acquity UPLC BEH C18 column 100 mm with mobile phase composition 1. 
The gradient profile started at 70% mobile phase A and 30 % mobile phase B and ended at 5% mobile phase A and 95% 
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Appx. Figure 3: The first sign of separation of lipids was achieved on Acquity UPLC BEH C18 VanGuard Pre-column 























Appx. Figure 4: E80 standard analysed on Acquity UPLC BEH C18 column 50 mm with mobile phase 
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Appx. Figure 5: Chromatogram obtained from full scan MS of standards 18:0-22:6Δ 4,7,10,13,16,19 PC, 16:0-18:1Δ9 PC and 16:0-0:0 PC 
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Appx. Figure 6: Standard 18:0-22:6Δ4,7,10,13,16,19 PC analysed on Acquity UPLC BEH C18 column 50 mm with mobile 

























Appx. Figure 7: All three PC standards analysed on Acquity UPLC BEH C18 column 50 mm with mobile 
phase composition 2 displayed in the top chromatogram. Below are the individual chromatograms for the 
different PC standards. 
 
All PC standards in one sample 
 101 
Appx. Figure 9: 16:0-18:1Δ9 PC analysed on Acquity UPLC BEH C18 column 50 mm with mobile phase composition 3.  


























Appx. Figure 11: MSE analysis of all PC standards on Acquity UPLC BEH C18 50mm column using mobile phase composition 3  
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Appx. Figure 12: Standard 18:0-22:6Δ4,7,10,13,16,19 PC analysed with mobile phase composition 3 on Acquity UPLC®  BEH C18  




















































Appx. Figure 13: MSE full scan spectra recorded for 18:0-22:6Δ4,7,10,13,16,19 PC upon CID. Analysed on Acquity UPLC 
BEH C18 column 50 mm using mobile phase gradient 2. 
m/z


































Appx. Figure 14: MSE full scan spectra recorded for 16:0-18:1Δ9 PC upon CID. Analysed on Acquity UPLC BEH C18 






























































Appx. Figure 15: MSE full scan spectra recorded for 18:0-22:6Δ4,7,10,13,16,19 PC upon CID. Analysed on 
Acquity UPLC BEH C18 column 50 mm using mobile phase gradient 3. 
m/z

























Appx. Figure 16: MSE full scan spectra recorded for 16:0-18:1Δ9 PC upon CID. Analysed on Acquity 
UPLC BEH C18 column 50 mm using mobile phase gradient 3. 
m/z




















Appx. Figure 17: MSE full scan spectra recorded for 18:1Δ9-0:0 PC upon CID. Analysed on Acquity UPLC BEH 
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Appx. Figure 21: Data acquired in continuum mode to be able to differentiate between the signals 283.2426 




MS/MS  experiments of 16:0-18:1Δ9 PC (CE 28V) and the ratio between R2COO-/ R1COO- fragment ions 
 [M-H] - = 758 [M-CH3] - = 744 
Experiment  Intensity 
of 



















1 100 48 2,08 100 80 1,25 
2 100 51 1,96 100 66 1,52 
3 100 47 2,13 100 64 1,56 
4 100 52 1,92 100 81 1,23 
5 100 47 2,13 100 82 1,22 
6 100 51 1,96 100 67 1,49 
7 100 49 2,04 100 62 1,61 
8 100 52 1,92 100 88 1,14 
9 100 49 2,04 100 87 1,15 

















Appx. Figure 22: Chromatogram obtained from analysis of 16:0-0:0 PE and 16:0-18:1Δ9 PE on analysed on Acquity 
UPLC®  BEH C18 VanGuard 5mm column with mobile phase composition 2.  
Appx. Figure 23: Chromatogram obtained from analysis of 16:0-18:1Δ9 PE using on Acquity UPLC BEH C18 column 













































Appx. Figure 24: MSE full scan spectra recorded for 16:0-18:1Δ9 PE upon CID. Analysed on Acquity UPLC BEH C18 
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Appx. Figure 27: Life krill oil capsules (1000 µg/ml) analysed on Acquity UPLC®  BEH C18 VanGuard 5mm column with mobile 
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Appx. Figure 30: Rimfrost Krill oil capsules (1000 µg/ml) analysed with mobile phase composition 3 on Acquity UPLC®  BEH C18 
column 150 mm using a 42 minute gradient. 
Appx. Figure 31: Rimfrost Krill oil capsules (1000µg/ml) analysed with mobile phase composition 3 on Acquity UPLC®  BEH C18 
column 150 mm using a 177 minute gradient. 
Appx. Figure 32: Rimfrost Krill oil capsules (1000µg/ml) analysed with mobile phase composition 3 on Acquity UPLC®  BEH C18 




































Appx. Figure 33: Rimfrost Krill oil capsules (1000 µg/ml) analysed with mobile phase composition 3 on Acquity UPLC®  BEH C18 
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Appx. Figure 34: Full scan MS of AN1 raw extract (4000 µg/ml) were analysed using the Acquity UPLC BEH C18 column 
50 mm and mobile phase composition 2 
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Appx. Figure 35: Full scan MS of AN2 raw extract (4000 µg/ml) were analysed using the Acquity UPLC BEH C18 column 
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Appx. Figure 36: Full scan MS of AN1 raw extract (4000 µg/ml) were analysed using the Acquity UPLC BEH C18 
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Appx. Figure 37: Full scan MS of AN2 raw extract (4000 µg/ml) were analysed using the Acquity UPLC BEH C18 
column 50 mm and mobile phase composition 3. 
 119 
Appx. Figure 38: Full scan MS of AN1 raw extract (4000 µg/ml) analysed with mobile phase composition 3 on Acquity UPLC®  BEH 
C18 column 150 mm using a 42 minute gradient. 
Appx. Figure 39: Full scan MS of AN1 raw extract 4000 µg/ml) analysed with mobile phase composition 3 on Acquity UPLC®  BEH C18 
column 150 mm using a 177 minute gradient. 
Appendix 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
